Journal of Clinical Immunology (2020) 40:24–64 https://doi.org/10.1007/s10875-019-00737-x ORIGINAL ARTICLE Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee Stuart G. Tangye 1,2 & Waleed Al-Herz 3 & Aziz Bousfiha 4 & Talal Chatila 5 & Charlotte Cunningham-Rundles 6 & Amos Etzioni 7 & Jose Luis Franco 8 & Steven M. Holland 9 & Christoph Klein 10 & Tomohiro Morio 11 & Hans D. Ochs 12 & Eric Oksenhendler 13 & Capucine Picard 14,15 & Jennifer Puck 16 & Troy R. Torgerson 12 & Jean-Laurent Casanova 17,18,19,20 & Kathleen E. Sullivan 21 Received: 4 November 2019 / Accepted: 18 December 2019 / Published online: 17 January 2020 # The Author(s) 2020, corrected publication 2020 Abstract We report the updated classification of Inborn Errors of Immunity/Primary Immunodeficiencies, compiled by the International Union of Immunological Societies Expert Committee. This report documents the key clinical and laboratory features of 430 inborn errors of immunity, including 64 gene defects that have either been discovered in the past 2 years since the previous update (published January 2018) or were characterized earlier but have since been confirmed or expanded upon in subsequent studies. The application of next-generation sequencing continues to expedite the rapid identification of novel gene defects, rare or common; broaden the immunological and clinical phenotypes of conditions arising from known gene defects and even known variants; and implement gene-specific therapies. These advances are contributing to greater understanding of the molecular, cellular, and immunological mechanisms of disease, thereby enhancing immunological knowledge while improving the management of patients and their families. This report serves as a valuable resource for the molecular diagnosis of individuals with heritable immunological disorders and also for the scientific dissection of cellular and molecular mechanisms underlying inborn errors of immunity and related human diseases. Keywords IUIS . primary immune deficiency . inborn errors of immunity . immune dysregulation . autoinflammatory disorders . next-generation sequencing Inborn errors of immunity, also referred to as primary immunodeficiencies, manifest as increased susceptibility to infectious diseases, autoimmunity, autoinflammatory diseases, allergy, and/or malignancy. These conditions are caused by monogenic germline mutations that result in loss of expression, loss-of-function (LOF; amorphic/hypomorphic), or gainof-function (GOF; hypermorphic) of the encoded protein [1, 2]. Heterozygous lesions may underlie autosomal dominant traits by GOF, haploinsufficiency, or negative dominance. Biallelic lesions typically cause autosomal recessive traits by LOF of the encoded protein (rarely GOF), while X-linked recessive traits arise from LOF of genes on the X chromosome, * Stuart G. Tangye s.tangye@garvan.org.au Extended author information available on the last page of the article either in the hemizygous state in males or in the homozygous state in females. Rare X-linked dominant traits can also arise from LOF or GOF variants. This results in aberrant immunity due to the critical roles of these proteins in the development, maintenance and function of cells of the immune system, or cells other than leukocytes that contribute to immunity, during homeostasis and in response to external (e.g., infectious agents or environmental antigens) and internal (e.g., cytokines, selfantigens and cancer cells) stimuli [3–5]. Inborn errors of immunity were traditionally considered to be rare diseases, affecting ~ 1 in 10,000 to 1 in 50,000 births. However, with ongoing discovery of novel inborn errors of immunity (Fig. 1a) and improved definition of clinical phenotypes [6–8], the collective prevalence of these conditions is more likely to be at least 1/ 1000–1/5000 [9]. Indeed, more common inborn errors have recently been described [10]. Regardless of their exact incidence and prevalence, inborn errors of immunity represent an unprecedented model to link defined monogenic defects with J Clin Immunol (2020) 40:24–64 25 Thus, the study of inborn errors of immunity has provided profound advances in the practice of precision molecular medicine. Since the early 1950s, when XLA was one of the first primary immune deficiencies to be described [16], clinical immunology has leveraged advances in the development of new methods to expedite the identification of defects of the immune system and the cellular, molecular, and genetic aberrations underlying these conditions. Indeed, the completion of the Human Genome Project in the early 2000s, coupled with rapid developments in next generation DNA sequencing (NGS) technologies, enabled the application of cost-effective and time-efficient sequencing of targeted gene panels, whole exomes, or whole genomes to cohorts of patients suspected of having a monogenic explanation for their disease. These platforms have led to a quantum leap in the identification and diagnosis of previously undefined genetically determined defects of the immune system (Fig. 1a, b; [6–8]). The International Union of Immunological Societies Expert Committee of Inborn Errors of Immunity comprises pediatric and adult clinical immunologists, clinician/scientists and researchers in basic immunology from across the globe (https://iuis.org/committees/iei/). A major objective and responsibility of the committee is to provide the clinical and research communities with an update of genetic causes of immune deficiency and dysregulation. The committee has existed since 1970 and has published an updated report approximately every 2 years to inform the field of these advances (Fig. 1a). In March 2019, the committee met in New York to discuss and debate the inclusion of genetic variants published over the preceding 2 years (since June 2017) [1, 2], as well as gene mutations that had appeared in the literature earlier but, based on newly available evidence, were now substantiated (Fig. 1b). Rather than simply including every gene variant reported, the committee applies very stringent criteria such that only those genes with convincing evidence of disease pathogenicity are classified as causes of novel inborn errors of immunity [17]. The Committee makes informed judgments for including new genetic causes of immunological conditions based on what we believe is most useful for practitioners caring for patients. Our current, and continuously evolving, practice is that criteria for inclusion can be met by several ways, for Fig. 1 Rate of discovery of novel inborn errors of immunity: 1983–2019. a The number of genetic defects underlying monogenic immune disorders as reported by the IUIS/WHO committee in the indicated year. b The number of pathogenic gene variants listed in each table by the IUIS committee. Report published in 2017, and the number of new genes for each table contained in this report (red bars). The numbers in each column correspond to the number of genes reported in the 2017 IUIS update (blue bars) [1, 2], the number of new genes for each table contained in this report (red bars), and the total number of genes for each table. Note: only data for Tables 1, 2, 3, 4, 5, 6, 7, and 8 are shown, because Table 9 (bone marrow failure) is a new addition to the current report. clinical phenotypes of immune dysregulation, in a broad sense of the term. As a committee, we are aware that human immunity involves cells other than circulating or tissue leukocytes and that it can be scaled up from the immune system to the whole organism. Inborn errors of immunity have unequivocally revealed non-redundant roles of single genes and their products in immune function [3, 4, 6–8], formed the basis of improved mechanism-based therapies for the immunopathology underlying many diseases [8, 11], established immunological paradigms representing the foundations of basic, clinical and translational immunology [3–5, 9, 12–14], and provided insights into the molecular pathogenesis of more common diseases [9, 15]. Clear examples of these include: & & & The initial description by Bruton of X-linked agammaglobulinemia (XLA) and the ability to treat this condition with antibody replacement therapy (the mainstay treatment for antibody deficiency diseases such as CVID) [16] The discovery of mutations in BTK [12] and the subsequent development of BTK-inhibitors such as ibrutinib for the treatment of B cell malignancies [14] Progressive CD4 T cell deficiency explains opportunistic infections secondary to HIV infection [9]. 26 instance peer-reviewed publication of (1) multiple cases from unrelated kindreds, including detailed immunologic data, or (2) very few cases, or even a single case (see below), for whom compelling mechanistic/pathogenic data is also provided, generally from parallel studies in an animal or cell culture model. Herein, we provide this latest update. The inborn errors of immunity are listed in 10 tables: Combined immunodeficiencies (Table 1), Combined immunodeficiencies with syndromic features (Table 2), Predominantly antibody deficiencies (Table 3), Diseases of immune dysregulation (Table 4), Congenital defects of phagocytes (Table 5), Defects in intrinsic and innate immunity (Table 6), Autoinflammatory diseases (Table 7), Complement deficiencies (Table 8), and Phenocopies of inborn errors of immunity (Table 10) (Fig. 1b). Since the last update (published January 2018) [1, 2], we have added a new table to consolidate genes that cause bone marrow failure (Table 9). Our division into phenotypes does not imply that the presentation is homogeneous. Rather, we recognize that substantial phenotypic and clinical heterogeneity exists within groups of patients with mutations in the same gene and even between individuals from the same pedigree with the identical gene mutation. To simplify the classification, each disorder has been listed only once, although distinct disorders due to mutations in the same gene, but with different modes of inheritance and pathogenic mechanisms are listed individually. Thus, several genes appear more than once in this update (some examples are listed below). Sub-divisions within each table segregate groups of disorders into coherent phenotypic sets. OMIM numbers are also provided within each table. If a OMIM number has not yet been issued for a particular genetic condition, then the number provided generally refers to the OMIM for that gene. Beneath each table, the new disorders added to this update are highlighted for easy reference. The advances in our understanding of clinical immunology continue to expand at a vast and remarkable rate, with the addition in this update of many—64, distributed across all tables (Fig. 1b)—novel genetic defects underlying inborn errors of immunity. Perhaps not surprisingly, most if not all of these new variants were identified by NGS, thus highlighting that whole exome/whole genome sequencing has become the gold standard for identifying novel pathogenic gene variants [6–8]. Indeed, since the first application of NGS to identify novel inborn errors of immunity was published in 2010 [18], ~ 45% of all currently known disease-causing variants have been discovered by whole exome/genome sequencing. Thus, a typical approach to identifying a pathogenic variant in a new patient might now consist of first sequencing a phenotype-driven panel of genes and advancing to whole exome/genome sequencing if the cause of disease remains elusive. J Clin Immunol (2020) 40:24–64 In this update, we increase the list of immunological diseases to 404, with 430 known genetic defects identified as causing these conditions. The unbiased application of NGS to the discovery and characterization of novel inborn errors of immunity continues to inform clinical and basic immunology. Thus, additional phenotypes have been identified for conditions resulting from variants in known and novel genes; the penetrance of genetic variants on clinical phenotypes has been shown to be highly variable; and clinical entities sharing common phenotypes have been discovered. For example, this update includes the findings that bi-allelic mutations in ZNF341 [19, 20], IL6ST (encoding gp130, a common component of the receptors for IL-6, IL-11, IL-27, LIF, OSM, CNTF) [21, 22], or IL6R [23, 24] all cause conditions that resemble autosomal dominant hyper-IgE syndrome due to dominant negative mutations in STAT3 [15]. Detailed analyses of these patients revealed a novel mechanism of regulating STAT3 signaling (via the transcription factor ZNF341) and defined the exact consequences of impaired IL-6/IL6R/gp130 and putatively IL-11/IL-11R/gp130 signaling to the phenotype of AD-HIES. Furthermore, key findings over the past 2 years continue to reveal that distinct mechanisms of disease (GOF, LOF, dominant negative, haploinsufficient), as well as different modes of inheritance (autosomal recessive, autosomal dominant) of variants in the same gene can cause disparate clinical conditions. This is a fascinating aspect of the genetics of human disease, and a salient reminder to be cognizant of the nature of the genetic variants identified from NGS. It is these genes that have several entries in this update. A few recent examples include: 1. Heterozygous variants in CARD11 [25, 26] or STAT5B [27] can be pathogenic due to negative dominance. This was potentially unexpected because autosomal recessive LOF variants in both of these genes were previously reported to cause combined immunodeficiency and severe immune dysregulation, respectively, yet heterozygous relatives of these affected individuals were healthy [28, 29]. 2. While heterozygous dominant negative mutations in TCF3, encoding the transcription factor E47, cause B cell deficiency and agammaglobulinemia [30], nonsense mutations in TCF3 have now been identified that are pathogenic only in an autosomal recessive state, as heterozygous carriers of these particular allelic variants remained healthy [31, 32]. 3. A heterozygous hypermorphic variant in IKBKB was found to cause a combined immunodeficiency [33] not too dissimilar to the original description of bi-allelic, recessive variants in IKBKB [34]. Similarly, bi-allelic LOF mutations in PIK3CD are now known to cause B cell deficiency and agammaglobulinemia [35–37], which is J Clin Immunol (2020) 40:24–64 quite distinct from the immune dysregulated state of individuals with monoallelic activating PIK3CD mutations [1, 37]. This observation nicely parallels the earlier findings of either homozygous or heterozygous mutations in PIK3R1 that clinically phenocopy recessive or activating mutations in PIK3CD respectively [1, 37]. 4. Distinct diseases can result from heterozygous mutations in IKZF1 (Ikaros): combined immunodeficiency due to dominant negative alleles [38] or CVID due to haploinsufficiency [39]. 5. Similar to STAT1 [40], variants in RAC2 [41–45] or CARD11 [25, 26, 28] can be pathogenic either as monoallelic GOF or LOF or bi-allelic recessive LOF. Thus, these findings have revealed the fundamental importance of elucidating the impact of a novel variant on the function of the encoded protein and thus the mechanism of pathogenicity. Furthermore, these new entries are an important reminder not to overlook the potential significance of identifying heterozygous variants in genes previously believed to cause disease only in a biallelic manner or to result in a previously defined specific clinical entity. Indeed, there are now at least 35 genes that have multiple entries in the current update, reflecting the distinct mechanisms by which variants result in or cause disease (e.g., STAT1, STAT3, NLRP1, RAC2, ZAP70, CARD11, IKBKB, WAS, JAK1, IFIH1, C3, C1R, C1S–GOF or LOF; STAT5, STAT1, CARD11, ACD, CFH, CFHR1–5, FOXN1, RAC2, TCF3, AICDA, PIK3R1, IFNGR1, TREX1, TICAM1, IRF8–AD or AR; PIK3CD–AD GOF, AR LOF; IKZF1– AD, or haploinsufficient; NLRP3—distinct disease phenotypes despite all resulting from GOF alleles). As noted above, genetic, biochemical, and functional analyses of putative novel pathogenic variants need to meet stringent criteria to be considered for inclusion in this update [17]. These criteria can make reporting genetic findings from single cases challenging, as often the best evidence that a novel variant is disease-causing is to identify additional, similarly affected but unrelated individuals with the same variants, or functionally similar variants in the same gene. While this can be challenging, particularly in light of the rarity of individual inborn errors of immunity, robust mechanistic laboratory investigations continue to provide compelling data from single patients, with or without evidence from animal models. Specifically, homozygous LOF mutations in IRF9 [46] and IL18BP [47] were identified and rigorously characterized in single patients and found to be the molecular cause of life-threatening influenza and fulminant viral hepatitis, respectively. The study and discovery of novel inborn errors of immunity can also enable improved patient management by 27 implementing gene-specific targeted therapies. Thus, JAK inhibitors are being used to treat disorders of immune dysregulation resulting from GOF mutations in JAK1, STAT1 or STAT3 [11], while mTOR inhibitors such as rapamycin or PI3K p110δ-specific inhibitors have been reported for the treatment of individuals with PIK3CD GOF or PIK3R1 LOF mutations [37]. Regarding novel gene defects, immune dysregulation due to DEF6 deficiency was successfully treated with abatacept (CTLA4-Ig) [48]. This correlated with impaired CTLA4 expression and function in DEF6-deficient T cells [48] and parallels the therapeutic use of abatacept and belatacept for LRBA-deficiency and CTLA4 haploinsufficiency, both of which are characterized by reduced CTLA4 expression in affected regulatory T cells [49, 50]. From a theoretical perspective, the finding that MSMD can be caused by mutations in IL12RB2, IL23R or SPPL2A and that these mutations are associated with impaired production of IFNγ—a requisite of anti-mycobacterial immunity—implies that IFNγ administration could be therapeutically beneficial in these clinical settings [51, 52]. Similarly, recombinant IL18BP could potentially ameliorate viral-induced liver toxicity due to IL18BP deficiency [47]. The goals of the IUIS Expert Committee on Inborn Errors of Immunity are to increase awareness, facilitate recognition, promote optimal treatment, and support research in the field of disorders of immunity. Thus, this 2019 Update and the accompanying “Phenotypical IUIS Classification” publications are intended as resources for clinicians and researchers. Importantly, these tables underpin the design of panels used for targeted gene sequencing to facilitate genetic diagnoses or inborn errors. In the past 5 years, the number of gene defects underlying inborn errors of immunity has nearly doubled from ~ 250 to 430 (Fig. 1a). The human genome contains 1800– 2000 genes that are known to be involved in immune responses [13]. Thus, the discovery and study of inborn errors of immunity has elegantly illustrated that > 20% of these immune genes play non-redundant roles in host defense and immune regulation. With the improved identification and phenotyping of patients with rare diseases, combined with high throughput genome sequencing, the number of genes fundamentally required for immunity will no doubt continue to increase, further revealing critical and novel roles for specific genes, molecules, pathways and cell types in immune responses, as well as mechanisms of disease pathogenesis and targets for immunotherapies. The field of inborn errors of immunity, and the global clinical and research communities, will therefore continue to provide key insights into basic and clinical immunology. PRKDC NHEJ1 LIG4 ADA AK2 RAC2 DNA PKcs deficiency Cernunnos/XLF deficiency DNA ligase IV deficiency Adenosine deaminase (ADA) deficiency AK2 defect Activated RAC2 defect CD40 AR 606843 308230 3. Combined immunodeficiency (CID), generally less profound than SCID CD40 ligand (CD154) deficiency CD40LG XL CD40 deficiency 602049 103020 608958 601837 611290 615966 605988 AD GOF AR AR AR AR AR DCLRE1C AR DCLRE1C (Artemis) deficiency 179615 179616 AR 2. T-B- SCID RAG deficiency RAG1 RAG2 600173 146661 151460 186790 186830 186780 605000 602354 AR AR AR AR AR AR AR AR Normal Normal to low Very low Very low Very low Very low Very low Very low Very low Very low Very low Very low Very low Very low Very low Very low Very low Normal to low Very low OMIM T cells 308380 Inheritance XL Genetic defect Immunodeficiencies affecting cellular and humoral immunity 1. T-B+ severe combined immune deficiency (SCID) γc deficiency (common gamma chain SCID, CD132 IL2RG deficiency) JAK3 deficiency JAK3 IL7Rα deficiency IL7R CD45 deficiency PTPRC CD3δ deficiency CD3D CD3ε deficiency CD3E CD3ζ deficiency CD3Z Coronin-1A deficiency CORO1A LAT deficiency LAT Disease Table 1 sIgM+IgD+ naïve B cells present; IgG+, IgA+, IgE+ memory B cells absent Very Low Very Low Low, decreasing Very low Very low Very low Very low Very low Normal to high Normal to high Normal Normal Normal Normal Normal Normal to low Normal to high B cells IgM normal or high, other Ig isotypes low Low, poor specific antibody responses Decreased Low, decreasing Decreased Decreased Variable Decreased Decreased Low Low Low Low Low Low Low High Low Ig Severe and opportunistic infections, idiopathic neutropenia; hepatitis and cholangitis, Cryptosporidium infections, cholangiocarcinoma; autoimmune blood cytopenias; peripheral neuroectodermal tumors Neutropenia, opportunistic infections, gastrointestinal and biliary tract and liver disease, Cryptosporidium infections Normal NK cell number, but increased risk of graft rejection, possibly due to activated NK cells Normal NK cell number, but increased risk of graft rejection, possibly due to activated NK cells, radiation sensitivity Normal NK, radiation sensitivity, microcephaly Normal NK, radiation sensitivity, microcephaly Normal NK, radiation sensitivity, microcephaly Low NK, bone defects, may have pulmonary alveolar proteinosis, cognitive defects Reticular dysgenesis with neutropenia; deafness Recurrent bacterial and viral infections, lymphoproliferation; neutropenia Low NK Normal NK Normal γ/δ Τ cells Normal NK, no γ/δ T cells Normal NK, no γ/δ T cells Normal NK, no γ/δ T cells Detectable thymus Typical SCID or combined immunodeficiency, the latter with adenopathy, splenomegaly, recurrent infections, autoimmunity Low NK Associated features 28 J Clin Immunol (2020) 40:24–64 ICOSLG CD3G CD8A ZAP70 ZAP70 TAP1 TAP2 TAPBP B2M CIITA RFXANK RFX5 RFXAP IKZF1 DOCK8 DOCK2 POLD1 POLD2 ICOSL deficiency CD3γ deficiency CD8 deficiency ZAP-70 deficiency (ZAP70 LOF) ZAP-70 combined hypomorphic and activating mutations MHC class I deficiency MHC class II deficiency group A, B, C, D DOCK8 deficiency DOCK2 deficiency Polymerase and deficiency IKAROS deficiency ICOS Genetic defect ICOS deficiency Disease Table 1 (continued) 269840 186910 186740 605717 604558 AR AR AR AR AR AR AR AD DN AR AR AR AR 174761 600815 603122 243700 600005 603200 601863 601861 603023 170260 170261 601962 109700 Low CD4 T cells T cell lymphopenia, reduced naïve CD8 T cells, increased exhausted CD8+ TEM cells, reduced MAIT, NKT cells, increased γδ T cells; poor proliferation; few Treg with poor function Low Low CD4+ T cells, reduced MHC II expression on lymphocytes no memory T cells Normal number, but low TCR expression Absent CD8, Normal CD4 Low CD8 number, normal CD4 number but with poor function Decreased CD8, normal or decreased CD4 cells Low CD8, normal CD4, absent MHC I on lymphocytes Low Normal OMIM T cells AR (LOF/GOF) 617006 AR AR AR AR AR Inheritance Normal increased total B cells, reduced memory B cells Poor peripheral B cell tolerance. no memory B cells Normal Normal Recurrent infections, may be asymptomatic May have immune dysregulation, autoimmunity Recurrent infections, autoimmunity, gastroenteritis, granulomas Recurrent bacterial and viral infections, neutropenia Immune deficiency and autoimmunity of variable severity Associated features Low igG IgG normal or low, poor antibody responses Low IgM, normal/high IgG and IgA, very high IgE, poor antibody responses Low Ig, Normal to low Early invasive herpes viral, bacterial infections, Normal NK cell number, but defective function. Poor interferon responses in hematopoietic and non-hematopoietic cells recurrent sinopulmonary infections, pneumocystis early CID onset Low NK cells with poor function. Eosinophilia, recurrent infections, cutaneous viral, fungal and staphylococcal infections, severe atopy/allergic disease, cancer diathesis Sinopulmonary infections, cutaneous granulomas. Absent β2m associated proteins MHC-I, CD1a, CD1b, and CD1c Failure to thrive, respiratory and gastrointestinal infections, liver/biliary tract disease Normal IgA, low IgM, Severe autoimmunity (bullous low/normal IgG; protective pemphigoid, inflammatory colitis Ab responses to vaccines Normal Vasculitis, pyoderma gangrenosum Normal Normal Normal or decreased Normal Normal Low Low Ig Normal Normal Low Normal B cells J Clin Immunol (2020) 40:24–64 29 RHOH STK4 TRAC LCK ITK MALT1 CARD11 BCL10 IL21 IL21R TNFRSF4 IKBKB STK4 deficiency TCRα deficiency LCK deficiency ITK deficiency MALT1 deficiency CARD11 deficiency BCL10 deficiency IL-21 deficiency IL-21R deficiency OX40 deficiency IKBKB deficiency Genetic defect RHOH deficiency Disease Table 1 (continued) AR AR AR AR AR AR LOF AR AR AR AR AR AR Inheritance 615592 615593 615207 615767 616098 615206 615468 186973 615758 615387 614868 602037 Normal number, low cytokine production, poor antigen proliferation Normal numbers, low antigen specific memory CD4+ Normal number, absent Treg and γ/δ T cells, impaired TCR activation Absent TCRαβ except for a minor CD3-dim TCRαβ population; most T cells γδ; poor proliferation Low CD4+, low Treg, restricted T cell repertoire, poor TCR signaling Progressive CD4 T cell lymphopenia; reduced T cell activation Normal number, poor proliferation Normal number, predominantly naïve T cells, poor proliferation Normal number, few memory T and Treg cells, poor antigen and anti-CD3 proliferation Normal number, normal/low function Normal, few naïve T cells, restricted repertoire, poor proliferation to CD3 CD4 lymphopenia, reduced naïve T cells, increased TEM and TEMRA cells, poor proliferation OMIM T cells Normal number, poor function Normal, decreased memory and switched B cells Normal numbers, low memory B cells Normal number, decreased memory and switched B cells Low, decreased memory and switched B cells Normal, transitional B cell predominance Normal Normal Low Normal Hypogammaglobulinemia, poor specific antibody responses; increased IgE Low Normal levels, poor specific antibody response Absent/low Normal to low serum Ig Normal IgG and IgA, high IgM Normal Normal Normal Reduced IgM, increased IgG, IgA, IgE; impaired Ab responses Normal Low B cells but normal maturation Normal Reduced memory B cells Ig B cells Recurrent bacterial, viral, fungal infections, opportunistic infections Impaired immunity to HHV8, Kaposi’s sarcoma Recurrent infections, Pneumocystis jiroveci, Cryptosporidium infections, liver disease Severe early onset colitis, recurrent sinopulmonary infections Recurrent bacterial and viral infections, candidiasis, gastroenteritis Pneumocystis jirovecii pneumonia, bacterial and viral infections EBV associated B cell lymphoproliferation, lymphoma, immune dysregulation Bacterial, fungal and viral infections Recurrent infections, immune dysregulation, autoimmunity Intermittent neutropenia, bacterial, viral (HPV, EBV, molluscum), candidal infections, lymphoproliferation, autoimmune cytopenias, lymphoma, congenital heart disease Recurrent viral, bacterial, fungal infections, immune dysregulation and autoimmunity, diarrhea Recurrent respiratory tract infections, skin infections, warts and molluscum, short stature, intellectual disability HPV infection, lung granulomas, molluscum contagiosum, lymphoma Associated features 30 J Clin Immunol (2020) 40:24–64 RELA MSN TFRC REL FCHO1 RelA haploinsufficiency Moesin deficiency TFRC deficiency c-Rel deficiency FCHO1 deficiency 613437 164910 616740 300988 618287 604758 604655 Low, poor proliferation Normal number, defective migration, proliferation Normal number, poor proliferation Normal, decreased memory CD4, poor proliferation Normal number, poor diversity, reduced proliferation to mitogens; no response to Ag Normal/increased Normal number, poor proliferation to antigen OMIM T cells Low Ig’s Ig Normal number, low memory B cells Low, mostly naïve; few switched memory B cells, impaired proliferation Normal number Low number Normal Normal Low, poor specific antibody responses Low Low Ig’s over time Normal Marked increase in B cell number Normal Ig levels but Impaired specific antibody responses Low, low switched memory B cells B cells Chronic mucocutaneous ulceration, Impaired NFkB activation; reduced production of inflammatory cytokines Recurrent infections with bacteria, varicella, neutropenia Recurrent infections, neutropenia, thrombocytopenia Recurrent infections with bacteria, mycobacteria, salmonella and opportunistic organisms. Defective innate immunity Recurrent infections (viral, mycobacteria, bacterial, fungal), lymphoproliferation, failure to thrive, increased activation-induced T cell death, defective clathrin-mediated endocytosis Low NK number and function, recurrent bacterial, viral and Cryptosporidium infections Recurrent infections Associated features SCID severe combined immunodeficiency, CID combined immunodeficiency, EBV Epstein-Barr virus, MHC major histocompatibility complex, HPV human papillomavirus, Treg T regulatory cell, XL Xlinked inheritance, AR autosomal recessive inheritance, AD autosomal dominant inheritance, LOF loss-of-function, GOF gain-of-function New inborn errors of immunity: 8; New inborn errors of immunity: 8; RAC2 GOF [42–45]; ICOSLG [53]; AD DN IKZF1 [38]; POLD1 [54, 55]; POLD2 [54]; RELA [56, 57]; REL [58]; FCHO1 [59] Total number of mutant genes: 58 Total number of disorders in Table 1: 50 SCID/CID spectrum: Infants with SCID who have maternal T cell engraftment may have T cells in normal numbers that do not function normally; these cells may cause autoimmune cytopenias or graft versus host disease. Hypomorphic mutations in several of the genes that cause SCID may result in Omenn syndrome (OS), or “leaky” SCID, or still less profound combined immunodeficiency (CID) phenotypes. Both OS and leaky SCID can be associated with > 300 autologous T cells/μL of peripheral blood and reduced, rather than absent, proliferative responses when compared with typical SCID caused by null mutations. A spectrum of clinical findings including typical SCID, OS, leaky SCID, CID, granulomas with T lymphopenia, autoimmunity and CD4 T lymphopenia can be found in an allelic series of RAG1/2 and other SCID-associated genes. There can be clinical overlap between some genes listed here and those listed in Table 7 AR AR AR XL AD AR RELB RelB deficiency Inheritance MAP3K14 AR Genetic defect NIK deficiency Disease Table 1 (continued) J Clin Immunol (2020) 40:24–64 31 Genetic defect BLM Bloom syndrome ZBTB24 DNMT3B Immunodeficiency with centromeric instability and facial anomalies (ICF types 1, 2, 3, 4) NBS1 Nijmegen breakage syndrome AR AR AR AR AR 2. DNA repair defects other than those listed in Table 1 Ataxia-telangiectasia ATM AR AR WIPF1 Arp2/3-mediated filament branching defect ARPC1B WIP deficiency XL B cells Normal numbers Normal Variably reduced 614064 Decreased or normal 602900 Decreased or normal, Decreased or normal responses to PHA may be decreased 604610 Normal 602667 Progressive decrease; may have low TRECs and T cells by NBS 607585 Progressive decrease, poor Normal proliferation to mitogens; may have low TRECs and T cells by newborn screening (NBS) 604223 Normal 602357 Reduced, defective Normal or low lymphocyte responses to anti-CD3 300392 Progressive decrease in Normal numbers numbers, abnormal lymphocyte responses to anti-CD3 Inheritance OMIM T cells Combined immunodeficiencies with associated or syndromic features 1. Immunodeficiency with congenital thrombocytopenia Wiskott-Aldrich syndrome (WAS LOF) WAS Disease Table 2 Associated features Often low IgA, IgE and IgG Ataxia, telangiectasia especially of sclerae; pulmonary infections; subclasses, increased IgM monomers; lymphoreticular and other malignancies; increased alpha antibodies variably decreased fetoprotein; increased radiosensitivity, chromosomal instability and chromosomal translocations Microcephaly, dysmorphic facies; Often low IgA, IgE, and IgG subclasses, lymphomas and solid tumors; increased IgM; increased radiosensitivity;, chromosomal instability antibodies variably decreased Low Short stature, dysmorphic facies sun-sensitive erythema; marrow failure; leukemia, lymphoma; chromosomal instability Hypogammaglobulinemia Facial dysmorphic features, developmental or delay, macroglossia; agammaglobulinemia, bacterial/opportunistic infections; variable antibody malabsorption; cytopenias; deficiency malignancies; multiradial configurations of chromosomes 1, 9, 16 Thrombocytopenia with small platelets, eczema, recurrent bacterial/viral infections, bloody diarrhea, lymphoma, autoimmune disease, IgA- nephropathy. Patients with XL-thrombocytopenia have later onset of complications and more favourable life expectancy but eventually develop similar complications as observed in WAS Normal, except for high Thrombocytopenia with or without small IgE platelets, recurrent bacterial and viral infections, eczema, bloody diarrhea; WAS protein absent Normal except for high IgA Mild thrombocytopenia with normal and IgE sized platelets, recurrent invasive infections; colitis, vasculitis, autoantibodies (ANA, ANCA), eosinophilia; defective Arp2/3 filament branching Low IgM and antibody responses to polysaccharides, often high IgA and IgE Ig 32 J Clin Immunol (2020) 40:24–64 AR AR AR POLE1 (Polymerase ε subunit 1) deficiency POLE1 (FILS syndrome) POLE2 (Polymerase ε subunit 2) deficiency POLE2 LIG1 NSMCE3 ERCC6L2 GINS1 Ligase I deficiency NSMCE3 deficiency ERCC6L2 (Hebo deficiency) GINS1 deficiency 3. Thymic defects with additional congenital anomalies DiGeorge/velocardio-facial syndrome Large deletion AD Chromosome 22q11.2 deletion syndrome (3 Mb) (22q11.2DS) typically in AR AR AR AR MCM4 MCM4 deficiency AR AR PMS2 AR HELLS 602054 Decreased or normal, 5% Normal have low TRECs at NBS and < 1500 CD3T cells/μL in neonatal period 610608 615667 608243 126391 602670 174762 602638 612688 600259 B cells Ig Associated features Normal or decreased Hypoparathyroidism; conotruncal cardiac malformation, velopalatal insufficiency; abnormal facies; intellectual disability Facial dysmorphic features, macroglossia; bacterial/opportunistic infections; malabsorption; cytopenias; malignancies; multiradial configurations of chromosomes 1, 9, 16 Normal Low B cells, switched Low IgG and IgA, high Recurrent infections; café-au-lait spots; and non-switched IgM, abnormal antibody lymphoma, colorectal carcinoma, responses brain tumors Normal Normal Low IgG or IgA Short stature, mild defect of motor control to ataxia; normal intelligence to learning difficulties; mild facial dysmorphism to microcephaly; increased radiosensitivity Normal Normal Normal NK cells: low number and function; viral infections (EBV, HSV, VZV); short stature; B cell lymphoma; adrenal failure Normal; decreased T cell Low memory B cells Low IgG2 and IgM, lack of Recurrent respiratory infections, proliferation antibody to PPS meningitis; facial dysmorphism, livido, short stature Lymphopenia, lack of Very low Hypogammaglobulinemia Recurrent infections, disseminated BCG TRECS at NBS, absent infections; autoimmunity (type 1 proliferation in response diabetes), hypothyroidism, facial to antigens dysmorphism Lymphopenia, increased γδ Normal Hypogammaglobulinemia, Recurrent bacterial and viral infections; T cells, decreased Reduced antibody growth retardation; sun sensitivity, mitogen response responses radiation sensitivity; macrocytic red blood cells Decreased number, poor Normal Normal IgG, IgA, normal Severe lung disease (possibly viral); responses to mitogens to elevated IgM; thymic hypoplasia; chromosomal breakage, radiation sensitivity and antigens decreased antibody responses to PPS Lymphopenia Low Normal Facial dysmorphism, microcephaly; bone marrow failure Low or normal Low or normal High IgA, low IgM and Neutropenia; IUGR; NK cells very low IgG AR CDCA7 609937 Decreased or normal; responses to PHA may be decreased 603946 Decreased or normal Inheritance OMIM T cells Genetic defect RNF168 deficiency (Radiosensitivity, RNF168 Immune Deficiency, Dysmorphic features, Learning difficulties [RIDDLE] syndrome) PMS2 deficiency Disease Table 2 (continued) J Clin Immunol (2020) 40:24–64 33 11q23del Chromosome 11q deletion syndrome (Jacobsen syndrome) SMARCAL1 MYSM1 Schimke immuno-osseous dysplasia MYSM1 deficiency RMRP Del10p13-p14 AD Chromosome 10p13-p14 deletion syndrome (10p13-p14DS) 4. Immuno-osseous dysplasias Cartilage hair hypoplasia (CHH) FOXN1 FOXN1 haploinsufficiency AR AR AR AD AD AR FOXN1 Winged helix nude FOXN1 deficiency AD AD Sporadic AD B cells Decreased Normal or decreased Ig Normal 612176 T cell lymphopenia, reduced B cell deficiency naïve T cells, low NK cells 606622 Decreased 157660 Varies from severely Normal decreased (SCID) to normal; impaired lymphocyte proliferation Hypogammaglobulinemia Normal Normal or reduced, antibodies variably decreased 600838 Severe T cell lymphopenia Normal/low Not assessed at birth, normalised by adulthood 601362 Normal, rarely lymphopenia Normal Normal and decreased lymphoproliferation to mitogens and antigens; hypoplastic thymus may be present 147791 Lymphopenia; low NK cells Decreased B cells and Hypogammaglobulinemia, switched memory decreased antibody B cells responses Decreased or normal 602054 Decreased or normal, may have low TRECs at NBS 608892 Decreased or normal, may Normal 608166 have low TRECs at NBS; response to PHA may be decreased 601705 Very low Normal Inheritance OMIM T cells CHD7 SEMA3E Unknown chromosome 22 (TBX1) Unknown TBX1 Genetic defect CHARGE syndrome DiGeorge/velocardio-facial syndrome TBX1 deficiency Disease Table 2 (continued) Short-limbed dwarfism with metaphyseal dysostosis; sparse hair; bone marrow failure; autoimmunity; susceptibility to lymphoma and other cancers; impaired spermatogenesis; neuronal dysplasia of the intestine Short stature, spondiloepiphyseal dysplasia, intrauterine growth retardation; nephropathy; bacterial, viral, fungal infections; may present as SCID; bone marrow failure Short stature; recurrent infections; congenital bone marrow failure, myelodysplasia; immunodeficiency affecting B cells and granulocytes; skeletal anomalies; cataracts; developmental delay Recurrent respiratory infections; multiple warts; facial dysmorphism, growth retardation Coloboma of eye; heart anomaly; choanal atresia; intellectual disability; genital and ear anomalies, CNS malformation; some are SCID-like Severe infections; abnormal thymic epithelium, immunodeficiency; congenital alopecia, nail dystrophy; neural tube defect Recurrent, viral and bacterial respiratory tract infections; skin involvement (eczema, dermatitis), nail dystrophy Hypoparathyroidism; renal disease; deafness; growth retardation; facial dysmorphism; cardiac defects may be present; recurrent infections ± Associated features 34 J Clin Immunol (2020) 40:24–64 ZNF341 ZNF341 deficiency AR-HIES ERBB2IP IL6ST IL6 signal transducer (IL6ST) deficiency ERBIN deficiency IL6R IL6 receptor deficiency STAT3 EXTL3 Immunoskeletal dysplasia with neurodevelopmental abnormalities (EXTL3 deficiency) 5. Hyper IgE syndromes (HIES) AD-HIES STAT3 deficiency (Job syndrome) RNU4ATAC Genetic defect MOPD1 deficiency (Roifman syndrome) Disease Table 2 (continued) AD AR AR AR AD LOF (dominant negative) AR AR B cells 606944 Increased circulating Treg 618282 Decreased Th17 and NK cells 618523 Decreased Th17 cells 147880 Normal/increased; normal responses to mitogens 147060 Normal overall; Th17, T follicular helper, MAIT, NKT cells decreased, Tregs may be increased; impaired responses to STAT3-activatng cytokines 617425 Decreased Recurrent bacterial infections; lymphadenopathy; spondyloepiphyseal dysplasia, extreme intrauterine growth retardation; retinal dystrophy; facial dysmorphism; may present with microcephaly; short stature Short stature; cervical spinal stenosis, neurodevelopmental impairment; eosinophilia; may have early infant mortality Associated features Distinctive facial features (broad nasal bridge); bacterial infections (boils, pulmonary abscesses, pneumatoceles) due to S. aureus, pulmonary aspergillus, Pneumocystis jirovecii; eczema, mucocutaneous candidiasis; hyperextensible joints, osteoporosis and bone fractures, scoliosis, retained primary teeth; coronary and cerebral aneurysms Normal total and Normal/low serum IgM, G, Recurrent pyogenic infections, cold memory B; A. Very high IgE; abscesses; high circulating IL-6 levels specific antibody reduced switched memory B production low Reduced switched High IgE, specific antibody Bacterial infections, boils, eczema, and non-switched production variably pulmonary abscesses, pneumatoceles; memory B cells affected bone fractures; scoliosis; retention of primary teeth; craniosynostosis Normal, reduced High IgE and IgG, specific Phenocopy of AD-HIES; mild facial memory B cells, antibody production dysmorphism; early onset eczema, impaired responses decreased MCC, bacterial skin infections, to abscesses, recurrent bacterial STAT3-activaitng respiratory infections (S. aureus), lung cytokines abscesses and pneumatoceles; hyperextensible joints; bone fractures and retention of primary teeth Normal Moderately increased IgE Recurrent respiratory infections, susceptibility to S. aureus, eczema; hyperextensible joints, scoliosis; arterial dilatation in some patients Decreased to normal Hypogammaglobulinemia, variably decreased specific antibodies Ig Very high IgE, specific Normal, reduced antibody production memory B cells, decreased BAFF expression increased, impaired responses to STAT3-activating cytokines Normal 601428 Decreased NK cell function Decreased total and memory B cells Inheritance OMIM T cells J Clin Immunol (2020) 40:24–64 35 SPINK5 PGM3 Comel-Netherton syndrome PGM3 deficiency AR Methylene-tetrahydrofolate dehydrogenase MTHFD1 1 (MTHFD1) deficiency EDA-ID due to IKBA GOF mutation NFKBIA AD GOF 7. Anhidrotic ectodermodysplasia with immunodeficiency (EDA-ID) EDA-ID due to NEMO/IKBKG deficiency IKBKG XL (ectodermal dysplasia, immune deficiency) AR AR AD LOF (dominant negative) AR AR AD Low switched and non-switched B cells Low B and memory B cells Normal B cells Variable Variable 164008 Normal total T cells, TCR activation impaired 300248 Normal or decreased, TCR activation impaired Associated features Decreased/poor antibody responses to conjugated polysaccharide antigens Decreased Decreased Megaloblastic anemia, pancytopenia; if untreated (B12) for prolonged periods results in intellectual disability Megaloblastic anemia, failure to thrive; if untreated for prolonged periods results in intellectual disability Recurrent bacterial infection, Pneumocystis jirovecii; megaloblastic anemia; failure to thrive; neutropenia; seizures, intellectual disability; folate-responsive Recurrent respiratory infectons; eczema, food allergies; hyper-extensible joints, scoliosis, retention of primary teeths; aortic aneurisms. High IgE and IgA, Congenital ichthyosis, bamboo hair, Antibody variably atopic diathesis; increased bacterial decreased infections; failure to thrive Normal or elevated IgG and Severe atopy; autoimmunity; bacterial IgA, most with high IgE, and viral infections; skeletal eosinophilia anomalies/dysplasia: short stature, brachydactyly, dysmorphic facial features; intellectual disability and cognitive impairment, delayed CNS myelination in some affected individuals Variable atopy, eczema, food allergies, High IgE, poor specific antibody production; eosinophilia; cutaneous viral impaired activation of infections, recurrent respiratory both NF-κB and infections; lymphoma; CID mTORC1 pathways Elevated IgE Ig Anhidrotic ectodermal dysplasia (in Normal; Low Decreased, some with some); various infections (bacteria, memory and elevated IgA, IgM, poor mycobacteria, viruses, fungi); colitis; isotype switched B specific antibody conical teeth, variable defects of skin, responses, absent cells antibodies to hair and teeth; monocyte dysfunction polysaccharide antigens Normal B cell Decreased IgG and IgA, Anhidrotic ectodermal dysplasia; various infections (bacteria, mycobacteria, numbers, impaired elevated IgM, poor BCR activation, specific antibody viruses, fungi); colitis; variable defects low memory and responses, absent 172460 Low thymic output, normal Low in vitro proliferation 229050 Variable numbers and activation profile 613441 Normal 617638 Normal overall, but Normal to low defective T cell activation and proliferation; skewing toward Th2 172100 CD8 and CD4 T cells may be decreased 605010 Normal 609192 Normal 610168 Inheritance OMIM T cells SLC46A1 SLC46A1/PCFT deficiency causing hereditary folate malabsorption 6. Defects of vitamin B12 and folate metabolism Transcobalamin 2 deficiency TCN2 CARD11 TGFBR1 TGFBR2 Loeys-Dietz syndrome (TGFBR deficiency) CARD11 deficiency (heterozygous) Genetic defect Disease Table 2 (continued) 36 J Clin Immunol (2020) 40:24–64 AR AR BCL11B EPG5 RBCK1 RNF31 CCBE1 FAT4 BCL11B deficiency EPG5 deficiency (Vici syndrome) HOIL1 deficiency HOIP deficiency Hennekam-lymphangiectasia-lymphedema syndrome AR AR AR AD AR SP110 Hepatic veno-occlusive disease with immunodeficiency (VODI) AR TTC7A AR AR PNP TTC37 SKIV2L AR AR AD GOF B cells Ig 612411 612753 612487 610924 615068 617237 604457 222470 614602 609332 Normal Normal Normal or low Normal Autoimmunity; EDA; non-progressive myopathy of skin, hair and teeth; T cell and monocyte dysfunction Recurrent bacterial, viral, fungal infections; variable ectodermal defects Associated features Autoimmune hemolytic anemia; neurological impairment Variable, but sometimes Normal or low Markedly decreased IgG, Bacterial (sepsis), fungal, viral infections; absent or low TRECs at IgM, IgA multiple intestinal atresias, often with NBS; may have SCID intrauterine polyhydramnios and early phenotype at birth demise Impaired IFNγ production Variably low numbers Hypogammaglobulinemia, Respiratory infections; IUGR; facial of switched may have low antibody dysmorphic features, wooly hair; early memory B cells responses onset intractable diarrhea, liver cirrhosis; platelet abnormalities Normal (decreased memory Normal (decreased Decreased IgG, IgA, IgM, Hepatic veno-occlusive disease; T cells) memory B cells) absent germinal center susceptibility to Pneumocystis jirovecii and tissue plasma cells pneumonia, CMV, candida; thrombocytopenia; hepatosplenomegaly; cerebrospinal leukodystrophy Low, poor proliferation Normal Normal Congenital abnormalities, neonatal teeth, dysmorphic facies; absent corpus callosum, neurocognitive deficits Profound depletion of Defective Decreased (particularly Agenesis of the corpus callosum; CD4+ cells IgG2) cataracts; cardiomyopathy; skin hypopigmentation; intellectual disability; microcephaly; recurrent infections, chronic mucocutaneous candidiasis Normal numbers Normal, decreased Poor antibody responses to Bacterial infections; autoinflammation; memory B cells polysaccharides amylopectinosis Normal numbers Normal, decreased decreased Bacterial infections; autoinflammation; memory B cells amylopectinosis; lymphangiectasia Low/variable Low/variable decreased Lymphangiectasia and lymphedema with facial abnormalities and other dysmorphic features Low/variable Low/variable decreased 164050 Progressive decrease 610277 Normal, defective TCR 605921 mediated activation isotype switched B antibody to cells polysaccharide antigens 618204 Decreased T cells, impaired Normal number, poor Reduced TCR activation function Inheritance OMIM T cells ORAI1 STIM1 IKBKB Genetic defect Tricho-Hepato-Enteric Syndrome (THES) 8. Calcium channel defects ORAI-1 deficiency STIM1 deficiency 9. Other defects Purine nucleoside phosphorylase (PNP) deficiency Immunodeficiency with multiple intestinal atresias EDA-ID due to IKBKB GOF mutation Disease Table 2 (continued) J Clin Immunol (2020) 40:24–64 37 STAT5B STAT5B KMT2D KDM6A KMT2A STAT5b deficiency STAT5b deficiency Kabuki syndrome (type 1 and 2) KMT2A deficiency (Wiedemann-Steiner syndrome) AD Decreased switched memory B cells B cells 605130 Normal Decreased switched and non-switched memory B cells Normal Normal 245590 Modestly decreased, Normal reduced Treg number and function 617744 Not reported AD 604260 Normal (dominant negative) AD 602113 Normal XL 300128 (females may be affected) AR AD Inheritance OMIM T cells Hypogammaglobulinemia, decreased antibody responses Low IgA and occasionally low IgG Increased IgE hypergammaglobulinemia, increased IgE Hypogammaglobulinemia, decreased antibody responses Ig Typical facial abnormalities, cleft or high arched palate, skeletal abnormalities, short stature; intellectual disability; congenital heart defects; recurrent infections (otitis media, pneumonia) in 50% of patients; autoimmunity may be present Respiratory infections; short stature; hypertelorism; hairy elbows; developmental delay, intellectual disability Lymphangiectasia and lymphedema with facial abnormalities and other dysmorphic features Recurrent respiratory and skin infections; growth retardation, developmental delay; white matter cerebral lesions; increased level of homocysteine; increased expression of stress response genes Growth-hormone insensitive dwarfism; dysmorphic features; eczema; lymphocytic interstitial pneumonitis; prominent autoimmunity Growth-failure; eczema (no immune defects compared to AR STAT5 deficiency) Associated features EDA ectodermal dysplasia anhydrotic, HSV herpes simplex virus, VZV varicella zoster virus, BCG Bacillus Calmette-Guerin, NBS newborn screen, TREC T cell receptor excision circle (biomarker for low T cells used in NBS), IUGR interuterine growth retardation Unknown cause of DiGeorge syndrome, unknown cause of CHARGE syndrome, unknown gene(s) within 10p13–14 deletion responsible for phenotype New inborn errors of immunity: 13; LIG1 [60]; FOXN1 haploinsufficiency [61]; IL6R [23, 24]; IL6ST [21, 22]; ZNF341 [19, 20]; ERBB2IP [62]; TGFBR1 [63]; TGFBR2 [63]; AD LOF CARD11 [25, 26]; AD GOF IKBKB [33]; SKIV2L [64]; NFE2L2 [65]; STAT5B AD DN [27] Total number of mutant genes in Table 2: 62 Total number of disorders in Table 2: 58 NFE2L2 Genetic defect Activating de novo mutations in nuclear factor, erythroid 2- like (NFE2L2) Disease Table 2 (continued) 38 J Clin Immunol (2020) 40:24–64 Genetic defect Predominantly antibody deficiencies Inheritance OMIM Ig TCF3 TCF3 SLC39A7 TOP2B E47 transcription factor deficiency SLC39A7 (ZIP7) deficiency Hoffman syndrome/TOP2B deficiency AD AR AD AR AR 126431 601416 616941 147141 615214 CD19 CD81 CD20 CD21 TNFRSF13B CD19 deficiency CD81 deficiency CD20 deficiency CD21 deficiency TACI deficiency# AR or AD AR AR AR AR AD AD PIK3R1 PTEN AD PIK3CD GOF PTEN deficiency (LOF) Activated p110δ syndrome (APDS) 604907 112210 120650 107265 186845 158350 616005 (APDS2) 615513 (APDS1) Low IgG, normal or elevated IgM and IgA Low IgG, impaired anti-pneumococcal response Low IgG and IgA and/or IgM Low IgG and IgA and/or IgM Low IgG, low or normal IgA and IgM Normal/Decreased Normal/increased IgM, reduced IgG and IgA 2. Severe reduction in at least 2 serum immunoglobulin isotypes with normal or low number of B cells, CVID phenotype Common variable immune deficiency Unknown Variable Low IgG and IgA and/or IgM with no gene defect specified (CVID) PIK3R1 p85 deficiency 1. Severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells, agammaglobulinemia BTK deficiency, X-linked BTK XL 300300 All isotypes decreased in majority of agammaglobulinemia (XLA) patients, some patients have detectable immunoglobulins μ heavy chain deficiency IGHM AR 147020 All isotypes decreased λ5 deficiency IGLL1 AR 146770 Igα deficiency CD79A AR 112205 Igβ deficiency CD79B AR 147245 BLNK deficiency BLNK AR 604515 p110δ deficiency PIK3CD AR 602839 Disease Table 3 Variable clinical expression and penetrance for monoallelic variants Clinical phenotypes vary: most have recurrent infections, some have polyclonal lymphoproliferation, autoimmune cytopenias and/or granulomatous disease Severe bacterial infections; reduced memory B cells and increased transitional B cells, EBV ± CMV viremia, lymphadenopathy/ splenomegaly, autoimmunity, lymphoproliferation, lymphoma Severe bacterial infections, reduced memory B cells and increased transitional B cells, lymphadenopathy/splenomegaly, lymphoproliferation, lymphoma; developmental delay Recurrent infections, Lymphoproliferation, Autoimmunity; developmental delay Recurrent infections, may have glomerulonephritis (CD81 mutation abolishes expression of CD19, thereby phenocopying CD19 mutations) Recurrent infections Recurrent infections Severe bacterial infections; autoimmune complications (IBD) Severe bacterial infections, cytopenias, decreased or absent pro-B cells Recurrent bacterial infections Severe, recurrent bacterial infections, failure to thrive Early onset infections, blistering dermatosis, failure to thrive, thrombocytopenia Recurrent infections, facial dysmorphism, limb anomalies Severe bacterial infections, normal numbers of pro-B cells Severe bacterial infections, normal numbers of pro-B cells Associated features J Clin Immunol (2020) 40:24–64 39 TNFRSF13C TNFSF12 Genetic defect AR AD Inheritance 606269 602695 OMIM Low IgG and IgM, Low IgM and A, lack of anti-pneumococcal antibody B cell deficiency and hypogammaglobulinemia Normal or low IgG, IgA, IgM, low or normal B cells, low memory B cells Ig Associated features Variable clinical expression Pneumonia, bacterial infections, warts, thrombocytopenia. Neutropenia TRNT1 deficiency TRNT1 AR 612907 Congenital sideroblastic anemia, deafness, developmental delay NFKB1 deficiency NFKB1 AD 164011 Recurrent sinopulmonary infections, COPD, EBV proliferation, autoimmune cytopenias, alopecia and autoimmune thyroiditis NFKB2 deficiency NFKB2 AD 615577 Low serum IgG, A and M; low B cell Recurrent sinopulmonary infections, numbers alopecia and endocrinopathies IKAROS deficiency IKZF1 AD 603023 Low IgG, IgA, IgM, low or normal Decreased pro-B cells, recurrent sinopulmonary (haploinsufficiencB cells; B cells and Ig levels reduce with infections; increased risk of ALL, y) age autoimmunity, CVID phenotype IRF2BP2 deficiency IRF2BP2 AD 615332 Hypogammaglobulinemia, absent IgA Recurrent infections, possible autoimmunity and inflammatory disease ATP6AP1 deficiency ATP6AP1 XL 300972 Variable immunoglobulin findings Hepatopathy, leukopenia, low copper ARHGEF1 deficiency ARHGEF1 AR 618459 Hypogammaglobulinemia; lack of antibody Recurrent infections, bronchiectasis SH3KBP1 (CIN85) deficiency SH3KBP1 XL 300310 IgM, IgG deficiency; loss of antibody Severe bacterial infections SEC61A1 deficiency SEC61A1 AD 609213 Hypogammaglobulinemia Severe recurrent respiratory tract infections RAC2 deficiency RAC2 AR 602049 Low IgG, IgA, IgM, low or normal Recurrent sinopulmonary infections, B cells; reduced Ab responses selective IgA deficiency; poststreptococcal following vaccination glomerulonephritis; urticaria Mannosyl-oligosaccharide glucosidase MOGS AR 601336 Low IgG, IgA, IgM, increased B cells; Bacterial and viral infections; severe deficiency poor Ab responses following vaccination neurologic disease; also known as congenital disorder of glycosylation type IIb (CDG-IIb) 3. Severe reduction in serum IgG and IgA with normal/elevated IgM and normal numbers of B cells, hyper IgM AID deficiency AICDA AR 6055258 IgG and IgA decreased, IgM increased; Bacterial infections, enlarged lymph nodes normal memory B cells but lacking and germinal centers; autoimmunity somatic hypermutation AD 605257 IgG absent or decreased, IgA undetected, Bacterial infections, enlarged lymph nodes IgM increased; normal memory and germinal centers. Mutations uniquely B cells with intact somatic hypermutation localize to the nuclear export signal. UNG deficiency UNG AR 191525 IgG and IgA decreased, IgM increased Enlarged lymph nodes and germinal centers INO80 deficiency INO80 AR 610169 IgG and IgA decreased, IgM increased Severe bacterial infections MSH6 deficiency MSH6 AR 600678 Variable IgG, defects, increased IgM Family or personal history of cancer in some, normal B cells, low switched memory B cells, Ig class switch recombination and somatic hypermutation defects 4. Isotype, light chain, or functional deficiencies with generally normal numbers of B cells Ig heavy chain mutations and deletions Mutation or AR One or more IgG and/or IgA subclasses May be asymptomatic chromosomal as well as IgE may be absent deletion at 14q32 AR 147200 All immunoglobulins have lambda light Asymptomatic Kappa chain deficiency IGKC chain Isolated IgG subclass deficiency Unknown ? Reduction in one or more IgG subclass BAFF receptor deficiency TWEAK deficiency Disease Table 3 (continued) 40 J Clin Immunol (2020) 40:24–64 ? Unknown CARD11 Unknown CARD11 GOF Selective IgM deficiency 616452 OMIM Usually asymptomatic, a minority may have poor antibody response to specific antigens and recurrent viral/bacterial infections Recurrent bacterial infections Associated features Absent IgA with other isotypes normal, May be asymptomatic Bacterial infections, normal subclasses and specific antibodies autoimmunity mildly increased Normal Reduced ability to produce antibodies to specific antigens IgG and IgA decreased Normal ability to produce antibodies to vaccine antigens, usually not associated with significant infections Polyclonal B cell lymphocytosis due Splenomegaly, lymphadenopathy, poor to constitutive NF-κB activation vaccine response Absent serum IgM Pneumococcal/bacterial Reduced IgA with decrease in one or more IgG subclass Ig # Heterozygous variants in TNFRSF13B have been detected in healthy individuals, thus such variants are likely to be disease-modifying rather than disease-causing EBV Epstein-Barr virus, COPD chronic obstructive pulmonary disease New disorders: 9: AR PIK3CD [35, 36, 66]; AR TCF3 [31, 32]; SLC39A7 [67]; TOP2B [68]; ARHGEF1 [69]; SH3KBP1 [70]; SEC61A1 [71]; AR LOF RAC2 [41]; AD AICDA Total number of mutant genes in Table 3: 39 Total number of disorders in Table 3: 46 Common variable immunodeficiency disorders (CVID) include several clinical and laboratory phenotypes that may be caused by distinct genetic and/or environmental factors. Some patients with CVID and no known genetic defect have markedly reduced numbers of B cells as well as hypogammaglobulinemia. Identification of causal variants can assist in defining treatment. In addition to monogenic causes on this table, a small minority of patients with XLP (Table 4), WHIM syndrome (Table 6), ICF (Table 2), VODI (Table 2), thymoma with immunodeficiency (Good syndrome), or myelodysplasia are first seen by an immunologist because of recurrent infections, hypogammaglobulinemia, and normal or reduced numbers of B cells ? AD GOF ? ? ? Inheritance Unknown Unknown Unknown Genetic defect Specific antibody deficiency with normal Ig levels and normal B cells Transient hypogammaglobulinemia of infancy May be asymptomatic Selective IgA deficiency IgG subclass deficiency with IgA deficiency Disease Table 3 (continued) J Clin Immunol (2020) 40:24–64 41 Genetic defect Inheritance OMIM Circulating T cells Diseases of immune dysregulation AR or AD AR STXBP2 FAAP24 SLC7A7 SLC7A7 deficiency IL2RB CTLA4 CD122 deficiency CTLA4 haploinsufficiency (ALPS-V) AD AR Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Circulating B cells 123890 Decreased Decreased 618495 Increased memory CD8 T cells, Increased decreased Tregs memory B cells 147730 Normal to decreased 617050 Normal AR AR AP3D1 603401 Normal 300292 Normal AR AP3B1 603868 Normal 606897 Increased activated T cells 222700 Normal 610884 Increased activated T cells 601717 605014 XL AR RAB27A 3. Regulatory T cell defects IPEX, immune FOXP3 dysregulation, polyendocrinopathy, enteropathy X-linked CD25 deficiency IL2RA Griscelli syndrome, type 2 Hermansky-Pudlak syndrome, type 2 Hermansky-Pudlak syndrome, type 10 2. FHL syndromes with hypopigmentation Chediak-Higashi LYST AR syndrome AR AR STX11 Syntaxin 11 deficiency (FHL4) STXBP2/Munc18–2 deficiency (FHL5) FAAP24 deficiency 1. Familial hemophagocytic lymphohistiocytosis (FHL syndromes) Perforin deficiency PRF1 AR 170280 Increased activated T cells (FHL2) UNC13D/Munc13–4 UNC13D AR 608897 Increased activated T cells deficiency (FHL3) Disease Table 4 Autoimmune enteropathy, early onset diabetes, thyroiditis hemolytic anemia, thrombocytopenia, eczema, elevated IgE and IgA Partial albinism, recurrent infections, pulmonary fibrosis, increased bleeding, neutropenia, HLH Oculocutaneous albinism, severe neutropenia, recurrent infections, seizures, hearing loss and neurodevelopmental delay Partial albinism, recurrent infections, fever, HSM, HLH, giant lysosomes, neutropenia, cytopenias, bleeding tendency, progressive neurological dysfunction Partial albinism, fever, HSM, HLH, cytopenias Lysinuric protein intolerance, bleeding tendency, alveolar proteinosis EBV-driven lymphoproliferative disease Fever, HSM, hemophagocytic lymphohistiocytosis (HLH), cytopenias Fever, HSM, HLH, cytopenias, Associated features No CD4 + C25+ cells with impaired Lymphoproliferation, autoimmunity, impaired T cell function of Tregs cells proliferation in vitro Diminished IL2Rβ expression, Lymphoproliferation, lymphadenopathy, dysregulated signaling in response to hepatosplenomegaly, autoimmune hemolytic IL-2/IL-15; increased immature NK anemia, dermatitis, enteropathy, cells hypergammaglobulinemia, recurrent viral (EBV, CMV) infections Impaired function of Tregs. Autoimmune cytopenias, enteropathy, interstitial lung disease, extra-lymphoid lymphocytic infiltration, recurrent infections Lack of (and/or impaired function of) CD4+ CD25+ FOXP3+ regulatory T cells (Tregs) Decreased NK and CTL activities (cytotoxicity and/or degranulation) Decreased NK and CTL activities (cytotoxicity and/or degranulation) Decreased NK and CTL activities (cytotoxicity and/or degranulation) Decreased NK and CTL activities (cytotoxicity and/or degranulation) Failure to kill autologous EBV transformed B cells. Normal NK cell function Hyper-inflammatory response of macrophages Normal NK cell function Decreased to absent NK and CTL activities cytotoxicity Decreased to absent NK and CTL activities (cytotoxicity and/or degranulation) Functional defect 42 J Clin Immunol (2020) 40:24–64 IL-10R deficiency IL10RA AR 146933 Normal 124092 Normal PEPD Prolidase deficiency 147795 Not assessed 5. Immune dysregulation with colitis IL-10 deficiency IL10 AR AD GOF JAK1 JAK1 GOF 190470 Decreased 613230 Normal AR Tripeptidyl-peptidase II TPP2 deficiency 606409 Not assessed AR AR ITCH ITCH deficiency Circulating B cells Functional defect Normal Normal Normal Not assessed Decreased Not assessed Leukocytes unresponsive to IL-10 No functional IL-10 secretion Peptidase D Itch deficiency may cause immune dysregulation by affecting both anergy induction in auto-reactive effector T cells and generation of Tregs TPP2 deficiency results in premature immunosenescence and immune dysregulation Hyperactive JAK1 606453 Normal or decreased CD4 Low or normal Reduced IgG and IgA in most numbers T cell dysregulation numbers of B cells DEF6 deficiency DEF6 AR 610094 Mild CD4 and CD8 Low or normal Impaired Treg function lymphopenia numbers of B cells STAT3 GOF mutation STAT3 AD GOF 102582 Decreased Decreased Enhanced STAT3 signaling, leading to increased Th17 cell differentiation, lymphoproliferation and autoimmunity. Decreased Tregs and impaired function BACH2 deficiency BACH2 AD 605394 Progressive T cell lymphopenia Impaired Haploinsufficiency for a critical lineage memory B specification transcription factor cell development FERMT1 deficiency FERMT1 AR 173650 Normal Normal Intracellular accumulation of IgG, IgM, IgA, and C3 in colloid bodies under the basement membrane 4. Autoimmunity with or without lymphoproliferation APECED (APS-1), AIRE AR or AD 240300 Normal Normal AIRE serves as check-point in the autoimmune thymus for negative selection of polyendocrinopathy autoreactive T cells and for generation with candidiasis and of Tregs ectodermal dystrophy AR Inheritance OMIM Circulating T cells LRBA Genetic defect LRBA deficiency Disease Table 4 (continued) Inflammatory bowel disease (IBD), folliculitis, recurrent respiratory diseases, arthritis, IBD, folliculitis, recurrent respiratory diseases, arthritis, lymphoma Autoimmunity: hypoparathyroidism, hypothyroidism, adrenal insufficiency, diabetes, gonadal dysfunction and other endocrine abnormalities; dental enamel hypoplasia, alopecia areata enteropathy, pernicious anemia; chronic mucocutaneous candidiasis Early-onset chronic lung disease (interstitial pneumonitis), autoimmunity (thyroiditis, type I diabetes, chronic diarrhea/enteropathy, and hepatitis), failure to thrive, developmental delay, dysmorphic facial features Variable lymphoproliferation, severe autoimmune cytopenias, hypergammaglobulinemia, recurrent infections HSM, eosinophilia, eosinophilic enteritis, thyroid disease, poor growth, viral infections Autoantibodies common, chronic skin ulcers, eczema, infections Dermatosis characterized by congenital blistering, skin atrophy, photosensitivity, skin fragility, and scaling Lymphocytic colitis, sinopulmonary infections Lymphoproliferation, solid organ autoimmunity, recurrent infections Enteropathy, hepatosplenomegaly, cardiomyopathy, recurrent infections Recurrent infections, inflammatory bowel disease, autoimmunity Associated features J Clin Immunol (2020) 40:24–64 43 AR TGFB1 RIPK1 RIPK1 618108 Reduced 618213 Normal 604708 Normal CASP10 CASP8 FADD ALPS-Caspase10 ALPS-Caspase 8 FADD deficiency AR AD AR AR 602457 Increased DN T cells 601762 Increased DN T cells 601763 Slightly increased DN T cells 134638 Increased DN T cells CD70 CTPS1 TNFRSF9 AR CD70 deficiency CTPS1 deficiency CD137 deficiency (41BB) AR AR AR CD27 CD27 deficiency XL XIAP XIAP deficiency (XLP2) 602250 615897 602840 615122 Reduced Memory B cells Normal Normal Normal Normal Normal or reduced Memory B cells Normal No memory B cells Normal number, low Treg, poor Decreased activation and function memory B cells Normal to low, but reduced Decreased activation, proliferation memory B cells Normal Normal 300079 Normal or Increased activated T cells; low/normal iNK T cells 7. Susceptibility to EBV and lymphoproliferative conditions SAP deficiency (XLP1) SH2D1A XL 300490 Normal or Increased activated T cells TNFSF6 ALPS-FASLG Leukocytes unresponsive to IL-10, and IL-22, IL-26, IL-28A, IL-28B and IL-29 Decreased memory B cells and plasmablasts Decreased T cell proliferation in response to anti-CD3 Functional defect Splenomegaly, adenopathies, autoimmune cytopenias, increased lymphoma risk, IgG and A normal or increased, elevated serum FasL, IL-10, vitamin B12 Splenomegaly, adenopathies, autoimmune cytopenias, SLE, soluble FasL is not elevated Adenopathies, splenomegaly, autoimmunity Adenopathies, splenomegaly, bacterial and viral infections, hypogammaglobulinemia Functional hyposplenism, bacterial and viral infections, recurrent episodes of encephalopathy and liver dysfunction Recurrent infections, early-onset IBD, progressive polyarthritis IBD, immunodeficiency, recurrent viral infections, microcephaly, and encephalopathy IBD, recurrent sinopulmonary infections Associated features Recurrent/chronic bacterial and viral infections (EBV, VZV), EBV lymphoproliferation, B cell non-Hodgkin lymphoma Low IgG, low IgA, poor responses to T EBV lymphoproliferation, B cell lymphoma, cell-dependent and T cell independent chronic active EBV infection Normal/high IgG poor proliferation to antigen hypogammaglobulinemia; poor Ab Features triggered by EBV infection, HLH, aplastic responses to some vaccines/infections anemia, low iNKT cells, B-lymphoma hypogammaglobulinemia; poor Ab EBV susceptibility, Hodgkin lymphoma; responses to some vaccines/infections autoimmunity in some patients Clinical and immunologic features triggered by EBV infection: HLH, Lymphoproliferation, Aplastic anemia, Lymphoma. Hypogammaglobulinemia, Absent iNKT cells Increased T cells susceptibility to EBV infection, Splenomegaly, lymphoproliferation apoptosis to CD95 and enhanced HLH, Colitis, IBD, hepatitis activation-induced cell death (AICD) Low iNKT cells Reduced NK cell and CTL cytotoxic activity Defective lymphocyte apoptosis Defective lymphocyte apoptosis and activation Defective lymphocyte apoptosis Apoptosis defect FASL mediated Apoptosis defect FAS mediated Normal/reduced Reduced activation of MAPK, NFkB pathways Normal Normal Normal Circulating B cells 6. Autoimmune lymphoproliferative syndrome (ALPS, Canale-Smith syndrome) ALPS-FAS TNFRSF6 AD 134637 Increased TCR α/β+ Normal, low AR CD4−CD8− double negative memory B (DN) T cells cells AR AD NFAT5 AR IL10RB 123889 Normal Inheritance OMIM Circulating T cells Genetic defect NFAT5 haploinsufficiency TGFB1 deficiency Disease Table 4 (continued) 44 J Clin Immunol (2020) 40:24–64 MAGT1 PRKCD X-linked magnesium EBV and neoplasia (XMEN) PRKCD deficiency Functional defect Low memory B Apoptotic defect in B cells cells, high CD5 B cells antigens, decreased T cell proliferation, IFNγ secretion, cytotoxicity Poor activation, Normal IgM, IgG, increased IgA proliferation, motility Normal B cell Normal to low, poor T dependent numbers, antibody response reduced memory B cells Normal but Progressive hypogammaglobulinemia decreased Reduced NK cell and CTL cytotoxic memory B activity due to impaired expression of cells NKG2D Circulating B cells Recurrent infections, EBV chronic infection, lymphoproliferation, SLE-like autoimmunity (nephrotic and antiphospholipid syndromes), low IgG EBV infection, lymphoma, viral infections, respiratory and GI infections Glycosylation defects Recurrent pneumonia, herpesvirus infections, EBV associated lymphoma Decreased NK cell function Recurrent bacterial, fungal and mycobacterial infections, viral warts, molluscum and EBV lymphoproliferative and other malignancy, atopy Associated features FHL familial hemophagocytic lymphohistiocytosis, HLH hemophagocytic lymphohistiocytosis, HSM hepatosplenomegaly, DN double-negative, SLE systemic lupus erythematous, IBD Inflammatory bowel disease New disorders: 7; SLC7A7 [72]; IL2RB [73, 74]; DEF6 [48]; FERMT1 [75]; TGFB1 [76]; RIPK1 [77, 78]; TNFRSF9 [66, 79, 80] Total number of mutant genes in Table 4: 45 Total number of disorders in Table 4: 44 AR XL CARMIL2 AR RLTPR deficiency 603962 Poor activation, proliferation, motility. Reduced naïve T cells 610859 Normal number, high CD4, increased naïve CD4+ and CD8+ T cells, low Treg and MAIT, poor CD28-induced function 300853 Low CD4 Low recent thymic emigrant cels, inverted CD4/CD8 ratio, reduced MAIT cells, poor proliferation to CD3 615559 Normal Inheritance OMIM Circulating T cells RASGRP1 AR Genetic defect RASGRP1 deficiency Disease Table 4 (continued) J Clin Immunol (2020) 40:24–64 45 XL AR VPS45 G6PT1 WAS LAMTOR2 TAZ VPS13B VPS45 deficiency (SCN5) Glycogen storage disease type 1b X-linked neutropenia/myelodysplasia P14/LAMTOR2 deficiency Barth Syndrome (3-Methylglutaconic aciduria type II) Cohen syndrome AR AR AR CEBPE SBDS DNAJC21 EFL1 HYOU1 SRP54 Specific granule deficiency Shwachman-Diamond Syndrome HYOU1 deficiency SRP54 deficiency ITGB2 AR CSF3R SMARCD2 G-CSF receptor deficiency SMARCD2 deficiency 2. Defects of motility Leukocyte adhesion deficiency type 1 (LAD1) AR AR JAGN1 CLPB AR AD AR AR AR AR USB1 Clericuzio syndrome (Poikiloderma with neutropenia) JAGN1 deficiency 3-Methylglutaconic aciduria AR XL GOF AR AR AR G6PC3 G6PC3 deficiency (SCN4) AD AR AD GFI1 HAX1 ELANE 1. Congenital neutropenias Elastase deficiency (Severe congential neutropenia [SCN] 1) Inheritance GFI 1 deficiency (SCN2) HAX1 deficiency (Kostmann Disease) (SCN3) Genetic defect Congenital defects of phagocyte number or function Disease Table 5 600065 604857 617052 617941 601746 607444 189965 138971 601736 616012 616254 613276 607817 300394 610389 300299 602671 610035 611045 600871 605998 130130 OMIM N+M + L + NK N N + HSC N + HSC N N N N N N N N N+L Mel N N+M N N+M N N N N N Affected cells Adherence, chemotaxis, endocytosis, T/NK cytotoxicity Protein translocation to ER, myeloid differentiation and neutrophil functional defect Unfolded protein response Stress granulopoiesis disturbed Chromatin remodeling, Myeloid differentiation and neutrophil functional defect Terminal maturation and global dysfunction Neutrophil maturation, chemotaxis, ribosomal biogenesis Myeloid differentiation Myeloid differentiation Mitochondrial protein Myeloid differentiation Myeloid differentiation Mitochondrial function Myeloid differentiation, chemotaxis, O2− production Differentiation, mitosis. Results from GOF mutations in GTPase binding domain of WASp Endosomal biogenesis Myeloid differentiation, migration Myeloid differentiation, chemotaxis, O2− production Myeloid differentiation Myeloid differentiation Myeloid differentiation Affected function Delayed cord separation, skin ulcers, periodontitis, leukocytosis Neutropenia, developmental aberrations, bones, hematopoietic stem cells, myelodysplasia Neutropenia, Neutrophils with bilobed nuclei Pancytopenia, exocrine pancreatic insufficiency, chondrodysplasia Pancytopenia, exocrine pancreatic insufficiency Hypoglycemia, inflammatory complications Neutropenia, exocrine pancreatic insufficiency Susceptibility to MDS/leukemia Severe congenital neutropenia or cyclic neutropenia B/T lymphopenia Cognitive and neurological defects in patients with defects in both HAX1 isoforms, susceptibility to MDS/leukemia Structural heart defects, urogenital abnormalities, inner ear deafness, and venous angiectasias of trunks and limbs Extramedullary hematopoiesis, bone marrow fibrosis, nephromegaly Fasting hypoglycemia, lactic acidosis, hyperlipidemia, hepatomegaly Neutropenia, myeloid maturation arrest, monocytopenia, variable lymphoid anomalies Neutropenia Hypogammaglobulinemia ↓CD8 cytotoxicity, partial albinism, growth failure Cardiomyopathy, myopathy, growth retardation, neutropenia Dysmorphism, mental retardation, obesity, deafness, neutropenia Retinopathy, developmental delay, facial dysmorphisms, poikiloderma Myeloid maturation arrest, osteopenia Neurocognitive developmental aberrations, microcephaly, hypoglycemia, hypotonia, ataxia, seizures, cataracts, IUGR Associated features 46 J Clin Immunol (2020) 40:24–64 AR AR XL ACTB FPR1 CTSC WDR1 CFTR MKL1 CYBB β actin deficiency Localized juvenile periodontitis Papillon-Lefèvre syndrome WDR1 deficiency Cystic fibrosis 614370 300770 137295 608508 618334 608512 608515 613960 305900 306400 606078 602421 604734 102630 136537 602365 608203 607901 605881 OMIM Alveolar macrophages Monocytes + peripheral DC N N+M N + M + L + NK M only N N+M N N+M N+M + L + NK N N+M Affected cells GM-CSF signaling Multi lineage cytopenias Reduced O2− production Killing (faulty O2− production) Impaired expression of cytoskeletal genes Chemotaxis Spreading, survival, chemotaxis Adherence, chemotaxis O2− production Motility Formylpeptide induced chemotaxis Chemotaxis Adherence, chemotaxis Rolling, chemotaxis Affected function Susceptibility to mycobacteria, HPV, histoplasmosis, alveolar proteinosis, MDS/AML/CMML, lymphedema Alveolar proteinosis Infections Infections, autoinflammatory phenotype, IBD McLeod phenotype in patients with deletions extending into the contiguous Kell locus Infections, autoinflammatory phenotype Mental retardation, short stature Periodontitis only Periodontitis, palmoplantar hyperkeratosis in some patients Mild neutropenia, poor wound healing, severe stomatitis, neutrophil nuclei herniate Respiratory infections, pancreatic insufficiency, elevated sweat chloride Mild thrombocytopenia Poor wound healing, leukocytosis Mild LAD type 1 features with hh-blood group, growth retardation, developmental delay LAD type 1 plus bleeding tendency Associated features MDS myelodysplastic syndrome, IUGR intrauterine growth retardation, LAD leukocyte adhesion deficiency, AML acute myelogenous leukemia, CMML chronic myelomonocytic leukemia, N neutrophil, M monocyte, MEL melanocyte, L lymphocyte, NK natural killer Removed: Cyclic neutropenia was merged with elastase deficiency New disorders: 3; SRP54 [81, 82]; DNAJC21 [83]; CYBC1 [84, 85] Total number of mutant genes in Table 5: 41 Total number of disorders in Table 5: 34 CSF2RA Pulmonary alveolar proteinosis CSFR2B AD GATA2 XL (Biallelic mutations in pseudo-autosomal gene) AR XL G6PD deficiency class I 4. Other non-lymphoid defects GATA2 deficiency AR AR CYBA CYBC1 NCF1 NCF2 NCF4 G6PD Autosomal recessive CGD Neutropenia with combined immune deficiency due to MKL1 deficiency 3. Defects of respiratory burst X-linked chronic granulomatous disease (CGD), gp91phox AD LOF RAC2 AD AR AR AR FERMT3 Leukocyte adhesion deficiency type 3 (LAD3) Rac2 deficiency AR Inheritance SLC35C1 Genetic defect Leukocyte adhesion deficiency type 2 (LAD2) Disease Table 5 (continued) J Clin Immunol (2020) 40:24–64 47 Genetic defect Defects in intrinsic and innate immunity RORC JAK1 RORγt deficiency JAK1 deficiency STAT2 IRF9 IRF7 IFNAR1 IFNAR2 STAT2 deficiency IRF9 deficiency IRF7 deficiency IFNAR1 deficiency IFNAR2 deficiency STAT1 TYK2 ISG15 P1104A TYK2 homozygosity ISG15 deficiency 3. Predisposition to severe viral infection STAT1 deficiency TYK2 Tyk2 deficiency TMC6 TMC8 CIB1 CXCR4 SPPL2A SPPL2a deficiency 2. Epidermodysplasia verruciformis (HPV) EVER1 deficiency EVER2 deficiency CIB1 deficiency WHIM (warts, hypogammaglobulinemia, infections, myelokathexis) syndrome IFNGR2 STAT1 CYBB IRF8 IFN-γ receptor 2 deficiency STAT1 deficiency Macrophage gp91 phox deficiency IRF8 deficiency 1. Mendelian susceptibility to mycobacterial disease (MSMD) IL-12 and IL-23 receptor β1 chain deficiency IL12RB1 IL-12p40 (IL-12 and IL-23) deficiency IL12B IL-12Rβ2 deficiency IL12RB2 IL-23R deficiency IL23R IFN-γ receptor 1 deficiency IFNGR1 Disease Table 6 AR AR AR AR AR AR LOF AD GOF AR AR LOF AR AR AR AR 602376 107450* 605047 147574* 600556 600555 605828 605829 618267 162643 147795 602943 176941 147571 611521 608238 226990 AR AR 601604 161561 601642 607562 209950 615978 147569 614892 300645 614893 OMIM AR AR AR AR AR AD AR AD LOF XL AD Inheritance Broadly expressed Leukocytes, plasmacytoid dendritic cells, non-hematopoietic cells Leukocytes and other cells Leukocytes and other cells Leukocytes and other cells Leukocytes and other cells Leukocytes Keratinocytes N+L L + NK L M+L M+L M L + NK M L + NK L + NK M+L M+L M+L M+L Macrophage only M+L Affected cells IFNAR1-dependent responses to IFN-α/β IFNAR2-dependent responses to IFN-α/β STAT1-dependent IFN-α/β, γ and λ responses STAT2-dependent IFN-α/β and λ response IRF9- and ISGF3-dependent IFN-α/β and λ responses IFN-α, β and γ production and IFN-λ production Increased response of the CXCR4 chemokine receptor to its ligand CXCL12 (SDF-1) EVER1, EVER2 and CIB1 form a complex in keratinocytes Lack of functional RORγT protein, IFNγ production defect, complete absence of IL-17A/F-producing T cells Reduced JAK1 activation to cytokines, Reduced IFNγ production Killing (faulty O2− production) Impaired development of cDCs and Th1* cells Lack of circulating monocytes and DCs, reduced NK cell numbers and function reported in some patients Impaired development of cDCs and Th1* cells Impaired cellular responses to IL-10, IL-12, IL-23, and type I IFNs Impaired cellular responses to IL-23 IFNγ production defect IFN-γ signaling IFN-γ binding and signaling IFN-γ secretion Affected function Severe disease caused by Yellow Fever vaccine and Measles vaccine Severe viral infections (disseminated vaccine-strain measles, HHV6) Severe viral infections, mycobacterial infection Severe viral infections (disseminated vaccine-strain measles) Severe influenza disease Human papillomavirus (HPV) (group B1) infections and cancer of the skin (typical EV) Warts (HPV) infection, neutropenia, low B cell number, hypogammaglobulinemia Susceptibility to mycobacteria and viruses, urothelial carcinoma Susceptibility to intracellular bacteria (mycobacteria, Salmonella), and viruses MSMD or tuberculosis Susceptibility to mycobacteria (BCG), brain calcification Susceptibility to mycobacteria and candida Susceptibility to mycobacteria and multiple other infectious agents including EBV Susceptibility to mycobacteria and Salmonella Isolated susceptibility to mycobacteria Susceptibility to mycobacteria Susceptibility to mycobacteria and Salmonella Associated features 48 J Clin Immunol (2020) 40:24–64 POLR3A POLR3C POLR3F RNA polymerase III deficiency TRAF3 TICAM1 TBK1 IRF3 DBR1 TRAF3 deficiency TRIF deficiency TBK1 deficiency IRF3 deficiency DBR1 deficiency TRAF3IP2 ACT1 deficiency MyD88 deficiency MYD88 7. TLR signaling pathway deficiency with bacterial susceptibility IRAK4 deficiency IRAK4 IL17RC IL17F STAT1 AR AR AR AR AD AD GOF AR 6. Predisposition to mucocutaneous candidiasis IL-17RA deficiency IL17RA IL-17RC deficiency IL-17F deficiency STAT1 GOF AR AR 602170 606883 607043 610925 606496 600555 605461 607212 607024 616532 604834 AR AD AD 607601 601896 608204 613002 614258 617454 617455 606951 146740 OMIM AD AD AR AD AR AD AD AD AR LOF AR Inheritance CARD9 5. Predisposition to invasive fungal diseases CARD9 deficiency UNC93B1 UNC93B1 deficiency TLR3 IFIH1 MDA5 deficiency 4. Herpes simplex encephalitis (HSE) TLR3 deficiency FCGR3A Genetic defect CD16 deficiency Disease Table 6 (continued) Lymphocytes + granulocytes+ monocytes Lymphocytes + granulocytes + monocytes T cells, fibroblasts T cells T cells, B cells, monocytes Epithelial cells, fibroblasts, mononuclear phagocytes Mononuclear phagocytes Central nervous system (CNS) resident cells and fibroblasts Leukocytes and other cells Broadly expressed NK cells Affected cells TIR-MyD88 signaling pathway TIR-IRAK4 signaling pathway IL-17RC signaling pathway IL-17F-containing dimers Gain-of-function STAT1 mutations that impair the development of IL-17-producing T cells Fibroblasts fail to respond to IL-17A and IL-17F, and their T cells to IL-17E IL-17RA signaling pathway CARD9 signaling pathway TBK1-dependent IFN-α, β and γ response Low IFN-α/β production in response to HSV1 and decreased IRF3 phosphorylation Impaired production of anti-viral IFNs UNC-93B-dependent IFN-α, β and γ response TRAF3-dependent IFN-α, β and γ response TRIF-dependent IFN-α, β and γ response TLR3-dependent IFN-α, β and γ response Viral recognition and IFN induction Impaired viral recognition and IFN induction in response to VZV or poly I:C Altered NK cells function Affected function Bacterial infections (pyogens) CMC CMC, folliculitis CMC, various fungal, bacterial and viral (HSV) infections, auto-immunity (thyroiditis, diabetes, cytopenias), enteropathy CMC, blepharitis, folliculitis, and macroglossia CMC, folliculitis Invasive candidiasis infection, deep dermatophytoses, other invasive fungal infections HSE of the brainstem. Other viral infections of the brainstem. Herpes simplex virus 1 encephalitis (incomplete clinical penetrance for all etiologies listed here); severe pulmonary influenza; VZV Herpes simplex virus 1 encephalitis Severe VZV infection Severe herpes viral infections, particularly VZV, Epstein-Barr virus (EBV), and (HPV) Rhinovirus and other RNA viruses Associated features J Clin Immunol (2020) 40:24–64 49 604113 601900 613736 613737 605254 611466 604592 603499 602642 614780 607649 603743 608025 601181 602727 141250 Leukocytes and other cells L+M Epidermis Stromal Somatic Somatic and hematopoietic Ubiquitous expression Osteoclasts Macrophages No spleen Lymphocytes + granulocytes + monocytes Lymphocytes + granulocytes + monocytes Affected cells IRF4 is a pleiotropic transcription factor IL-18BP neutralizes secreted IL-18 Notch signaling/gamma-secretase in hair follicle regulates keratinization Osteoclastogenesis Osteoclastogenesis RPSA encodes ribosomal protein SA, a component of the small subunit of the ribosome HO-1 regulates iron recycling and heme-dependent damage occurs Pore forming serum protein ER stress Nuclear pore Secretory lysosomes TIRAP- signaling pathway, TLR1/2, TLR2/6, and TLR4 agonists were impaired in the fibroblasts and leukocytes TIR-IRAK1 signaling pathway Affected function Fulminant viral hepatitis Whipple’s disease Trypanosomiasis Fever induces liver failure Fever induces acute encephalopathy Osteopetrosis with hypocalcemia, neurologic features Osteopetrosis with visual impairment Osteopetrosis with hypocalcemia, neurologic features Osteopetrosis Osteopetrosis with hypocalcemia Osteopetrosis Osteopetrosis with severe growth retardation Verneuil’s disease/Hidradenitis suppurativa with acne Verneuil’s disease/Hidradenitis suppurative with cutaneous hyperpigmentation Verneuil’s disease/Hidradenitis suppurativa Hemolysis, nephritis, inflammation Bacteremia (encapsulated bacteria) Bacterial infections, X-linked MECP2 deficiency-related syndrome due to a large de novo Xq28 chromosomal deletion encompassing both MECP2 and IRAK1 Staphylococcal disease during childhood Associated features NF-κB nuclear factor kappa B, TIR Toll and Interleukin 1 receptor, IFN interferon, TLR Toll-like receptor, MDC myeloid dendritic cell, CNS central nervous system, CMC chronic mucocutaneous candidiasis, HPV human papillomavirus, VZV varicella zoster virus, EBV, Epstein-Barr virus New genes: 13, IL12RB2 [51]; IL23R [51]; SPPL2A [52]; TYK2 P1104A allele [10]; CIB1 [86]; IRF9 [46]; IFNAR1 [87]; POLR3A [88]; POLR3C [88]; POLR3F [89]; DBR1 [90]; IRF4 [91]; IL18BP [47] Total number of mutant genes in Table 6: 64 Total number of disorders in Table 6: 53 AR AD 9. Other inborn errors of immunity related to leukocytes IRF4 haploinsufficiency IRF4 IL18BP AD PSENEN IL-18BP deficiency AD AR AR AR AR PLEKHM1 TCIRG1 TNFRSF11A TNFSF11 PSEN AR AR SNX10 OSTM1 AD AD AR AR AR APOL1 NBAS RANBP2 CLCN7 AR NCSTN Hidradenitis suppurativa Trypanosomiasis Acute liver failure due to NBAS deficiency Acute necrotizing encephalopathy Osteopetrosis HMOX 271400 8. Other inborn errors of immunity related to non-hematopoietic tissues Isolated congenital asplenia (ICA) RPSA AD 300283 OMIM 614382 TIRAP TIRAP deficiency XL Inheritance AR IRAK1 Genetic defect IRAK1 deficiency Disease Table 6 (continued) 50 J Clin Immunol (2020) 40:24–64 RNASEH2B AR RNASEH2C AR RNASEH2A AR SAMHD1 ADAR1 IFIH1 DNASE2 DNASE1L3 AR ACP5 POLA1 RNASEH2B deficiency, AGS2 RNASEH2C deficiency, AGS3 RNASEH2A deficiency, AGS4 SAMHD1 deficiency, AGS5 ADAR1 deficiency, AGS6 Aicardi-Goutieres syndrome 7 (AGS7) DNAse II deficiency Pediatric systemic lupus erythematosus due to DNASE1L3 deficiency Spondyloenchondro-dysplasia with immune dysregulation (SPENCD) X-linked reticulate pigmentary disorder XL AR AR AD GOF AR AR AR TREX1 TREX1 deficiency, Aicardi-Goutieres syndrome 1 (AGS1) AR AR ADA2 TMEM173 1. Type 1 interferonopathies STING-associated vasculopathy, infantile-onset (SAVI) 301220 171640 614420 126350 615846 146920 606754 610326 610330 606034 606609 607575 612374 Inheritance OMIM ADA2 deficiency Genetic defect Autoinflammatory disorders Disease Table 7 Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed T cells Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed Not assessed B cells AGS Classical AGS, SLE, SP, SMS Classical AGS, BSN, SP Classical AGS, FCL Classical AGS, SP Classical AGS Classical AGS Polyarteritis nodosa, childhood-onset, early-onset recurrent ischemic stroke and fever; some patients develop hypogammaglobulinemia Classical AGS, SLE, FCL Skin vasculopathy, inflammatory lung disease, systemic autoinflammation and ICC, FCL Associated features Very early onset SLE, reduced complement levels, autoantibodies (dsDNA, ANCA), lupus nephritis, hypocomplementemic urticarial vasculitis syndrome Short stature, SP, ICC, SLE, thrombocytopenia and autoimmune hemolytic anemia, possibly recurrent bacterial and viral infections POLA1 is required for synthesis of Hyperpigmentation, characteristic facies, cytosolic RNA:DNA and its lung and GI involvement deficiency leads to increase production of type I interferon STING activates both the NF-kappa-B and IRF3 transcription pathways to induce expression of IFN ADAs deactivate extracellular adenosine and terminate signaling through adenosine receptors Intracellular accumulation of abnormal ss DNA species leading to increased type I IFN production Intracellular accumulation of abnormal RNA-DNA hybrid species leading to increased type I IFN production Controls dNTPs in the cytosol, failure of which leads to increased type I IFN production Catalyzes the deamination of adenosine to inosine in dsRNA substrates, failure of which leads to increased type I IFN production IFIH1 gene encodes a cytoplasmic viral RNA receptor that activates type I interferon signaling through the MAVS adaptor molecule DNAse II degrades and eliminates DNA. Loss of DNase II activity induces type I interferon signaling DNASE1L3 is an endonuclease that degrades extracellular DNA. DNASE1L3 deficiency decreases clearance of apoptotic cells Upregulation of IFN through mechanism possibly relating to pDCS Functional defect J Clin Immunol (2020) 40:24–64 51 134610 AD AD GOF NLRP1 GOF NLRP1 AR AD GOF AD GOF 611762 AD GOF NLRC4-MAS (macrophage NLRC4 activating syndrome) Familial cold autoinflammatory syndrome 4 PLAID (PLCγ2 associated PLCG2 antibody deficiency and immune dysregulation) Familial cold autoinflammatory syndrome 3 or APLAID (c2120A > C) NLRP1 deficiency NLRP1 607115 AD GOF Neonatal onset multisystem inflammatory disease (NOMID) or chronic infantile neurologic cutaneous and articular syndrome (CINCA) Familial cold autoinflammatory NLRP12 syndrome 2 615225 617388 614468 614878 616115 616050 191900 120100 AD GOF AD GOF NLRP3 260920 AR MVK Mevalonate kinase deficiency (Hyper IgD syndrome) Muckle-Wells syndrome Familial cold autoinflammatory syndrome 1 249100 AR LOF 2. Defects affecting the inflammasome Familial Mediterranean fever MEFV 164350 AD GOF OAS1 607057 OAS1 deficiency AR Inheritance OMIM USP18 Genetic defect USP18 deficiency Disease Table 7 (continued) Keratinocytes leukocytes B cells, NK, Mast cells PMNs monocytes macrophages PMNs, monocytes PMNs, chondrocytes Mature granulocytes, cytokine-activated monocytes. Mature granulocytes, cytokine-activated monocytes. Somatic and hemaotpoietic PMNs Monocytes PMNs, monocytes Not assessed T cells Associated features Periodic fever and leukocytosis with high IgD levels Urticaria, SNHL, amyloidosis. Non-pruritic urticaria, arthritis, chills, fever and leukocytosis after cold exposure. Neonatal onset rash, chronic meningitis, and arthropathy with fever and inflammation. Recurrent fever, serositis and inflammation responsive to colchicine. Predisposes to vasculitis and inflammatory bowel disease. Defective negative regulation of TORCH-like syndrome ISG15 leading to increased IFN Increased interferon from Pulmonary alveolar proteinosis, recognition of RNA skin rash Functional defect Systemic elevation of IL-18 and caspase 1, suggesting involvement of NLRP1 inflammasome Increased IL1β Palmoplantar carcinoma, corneal scarring; recurrent respiratory papillomatosis Dyskeratosis, autoimmunity and arthritis Non-pruritic urticaria, arthritis, chills, fever and leukocytosis after cold exposure. Gain of function mutation in NLRC4 Severe enterocolitis and results in elevated secretion of macrophage activation syndrome IL-1β and IL-18 as well as macrophage activation Mutations activate IL-1 pathways Cold urticaria hypogammaglobulinemia, impaired humoral immunity, autoinflammation affecting cholesterol synthesis, pathogenesis of disease unclear Defect in cryopyrin, involved in leukocyte apoptosis and NFkB signaling and IL-1 processing Usually M694del variant. Increased inflammasome-mediated induction of IL1β. Low Not assessed B cells 52 J Clin Immunol (2020) 40:24–64 Genetic defect COPA OTULIN COPA defect Otulipenia/ORAS PSMG2 PSMB8* SLC29A3 CANDLE (chronic atypical neutrophilic dermatitis with lipodystrophy) AR IL36RN SH3BP2 AR IL1RN Cherubism AR LPIN2 Chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia (Majeed syndrome) DIRA (Deficiency of the Interleukin 1 Receptor Antagonist) DITRA (Deficiency of IL-36 receptor antagonist) SLC29A3 mutation CARD14 AR ADAM17 ADAM17 deficiency CAMPS (CARD14 mediated psoriasis) AD NOD2 602723 602782 614204 612852 609628 614328 186580 604416 B cells Mainly in keratinocytes Destructive arthritis, inflammatory skin rash, myositis Recurrent fever, serositis, rash, and ocular or joint inflammation Functional defect Undefined Associated features Hyperpigmentation hypertrichosis, histiocytosis-lymphadenopathy plus syndrome Psoriasis Pustular psoriasis Chronic recurrent multifocal osteomyelitis, transfusion-dependent anemia, cutaneous inflammatory disorders Neonatal onset of sterile multifocal osteomyelitis, periostitis and pustulosis. Mutations in nucleotide binding site Uveitis, granulomatous synovitis, of CARD15, possibly disrupting camptodactyly, rash and cranial interactions with neuropathies, 30% develop lipopolysaccharides and NF-kB Crohn colitis signaling Defective TNFα production Early onset diarrhea and skin lesions PMNs, Monocytes Mutations in the IL1 receptor antagonist allow unopposed action of Interleukin 1 Keratinocytes, Mutations in IL-36RN leads to leukocytes increase IL-8 production Leukocytes, bone – cells Leukocytes and epithelial cells Neutrophils, bone marrow cells Monocytes PMNs, monocytes Mutations of 55-kD TNF receptor leading to intracellular receptor retention or diminished soluble cytokine receptor available to bind TNF Hematopoietic Disordered actin reorganization tissues, leading to compromised upregulated in physiologic signaling during activated T cells inflammatory response T cells Mutations in CARD14 activate the NF-kB pathway and production of IL-8 AD 118400 Stroma cells, bone Hyperactived macrophage and Bone degeneration in jaws cells increase NF-kB AR and AD 256040 Keratinocytes, B Mutations cause increased IFN Contractures, panniculitis, ICC, fevers cell adipose signaling through an undefined cells mechanism AR 609702 Lymphocytes Panniculitis, lipodystrophy, autoimmune hemolytic anemia AD 6011924 PMN and tissue Defective intracellular transport via Autoimmune inflammatory arthritis and specific cells the coat protein complex I (COPI) interstitial lung disease with Th17 dysregulation and autoantibody production AR 615712 Leukocytes Increase LUBAC induction of Fever, diarrhea, dermatitis NF-KB activation leading to high proinflamatory cytokines levels. AD AR AD PSTPIP1 Pyogenic sterile arthritis, pyoderma gangrenosum, acne (PAPA) syndrome, hyperzincemia and hypercalprotectinemia Blau syndrome 142680 Inheritance OMIM 3. Non-inflammasome-related conditions TNF receptor-associated periodic TNFRSF1A AD syndrome (TRAPS) Disease Table 7 (continued) J Clin Immunol (2020) 40:24–64 53 AP1S3 ALPI TRIM22 HAVCR2 AP1S3 deficiency ALPI deficiency TRIM22 T cell lymphoma subcutaneous panniculitis-like (TIM3 deficiency) AR AR AR AR AD 618398 606559 615781 171740 616744 Inheritance OMIM B cells Defective inhibition of NF-KB signaling pathway Keratinocytes Disrupted TLR3 translocation Intestinal epithelial Deficient inhibition of LPS in cells intestine Macrophages, Granulomatous colitis intestinal epithelial cells Leukocytes Increased inflammasome activity due to defective checkpoint signaling Lymphocytes T cells Associated features Panniculitis, HLH, polyclonal cutaneous T cell infiltrates or T cell lymphoma Inflammatory bowel disease Pustular psoriasis Inflammatory bowel disease Arthralgia, mucosal ulcers, ocular inflammation Functional defect *Variants in PSMB4, PSMB9, PSMA3, and POMP have been proposed to cause a similar CANDLE phenotype in compound heterozygous monogenic (PSMB4), digenic (PSMA3/PSMB8, PSMB9/PSMB4, PSMB4/PSMB8) and AD monogenic (POMP) models [92] IFN interferon, HSM hepatosplenomegaly, CSF cerebrospinal fluid, SLE systemic lupus erythematosus, TORCH toxoplasmosis, other, rubella, cytomegalovirus, and herpes infections, SNHL sensorineural hearing loss, AGS Aicardi-Goutières syndrome, BSN bilateral striatal necrosis, FCL familial chilblain lupus, ICC intracranial calcification, IFN interferon type I, pDCs plasmacytoid dendritic cells, SP spastic paraparesis, SMS Singleton-Merten syndrome, ss single-stranded DNA New disorders: 9; DNASE2 [93]; DNASE1L3 [94–96]; OAS1 [97]; AD MEFV; NLRP1 GOF [98, 99]; ALPI [100]; TRIM22 [101]; PSMG2 [102]; HAVCR2 [103, 104] Total number of mutant genes in Table 7: 42 Total number of disorders in Table 7: 45 TNFAIP3 Genetic defect A20 deficiency Disease Table 7 (continued) 54 J Clin Immunol (2020) 40:24–64 C1QA C1QB C1QC C1R C1R C1S C1S C4A + C4B C2 C3 C3 C5 C6 C7 C8A C8G C8B C9 MASP2 FCN3 SERPING1 CFB CFB C1q deficiency due to defects C1r Periodontal Ehlers-Danlos C1s deficiency C1s Periodontal Ehlers-Danlos Complete C4 deficiency C2 deficiency C3 deficiency (LOF) C3 GOF C5 deficiency C6 deficiency C7 deficiency C8α deficiency C8 γ deficiency C8 β deficiency C9 deficiency MASP2 deficiency Ficolin 3 deficiency C1 inhibitor deficiency Factor B GOF Factor B deficiency C1r deficiency Genetic defect Complement deficiencies Disease Table 8 AR AD GOF AD AR AR AR AR AR AR AR AR AD GOF AR AR AR AD GOF AR AD GOF AR AR AR AR AR Inheritance 615561 612924 606860 604973 605102 120960 120940 217050 217070 120950 120930 120700 120900 120700 217000 613785 120810 613785 613785 120550 120570 120575 613785 Gene OMIM Reduced CH50 and AP50 hemolytic activity, deficient bactericidal activity Deficient activation of the lectin activation pathway Absence of complement activation by the Ficolin 3 pathway. Spontaneous activation of the complement pathway with consumption of C4/C2, spontaneous activation of the contact system with generation of bradykinin from high molecular weight kininogen Gain-of-function mutation with increased spontaneous AH50 Deficient activation of the alternative pathway Normal CH50 Absent CH50 hemolytic activity, defective activation of the classical pathway, complete deficiency requires biallelic mutations/ deletions/conversions of both C4A and C4B Absent CH50 hemolytic activity, defective activation of the classical pathway Absent CH50 and AH50 hemolytic activity, defective opsonization, defective humoral immune response Increased activation of complement Absent CH50 and AH50 hemolytic activity Defective bactericidal activity Absent CH50 and AH50 hemolytic activity, defective bactericidal activity Absent CH50 hemolytic activity, defective activation of the classical pathway Normal CH50 Absent CH50 hemolytic activity, defective activation of the classical pathway Absent CH50 hemolytic activity, defective activation of the classical pathway, diminished clearance of apoptotic cells Laboratory features Infections with encapsulated organisms Atypical hemolytic-uremic syndrome Hereditary angioedema Mild susceptibility to disseminated neisserial infections Pyogenic infections, inflammatory lung disease, autoimmunity Respiratory infections, abscesses Hyperpigmentation, skin fragility SLE, infections with encapsulated organisms, partial deficiency is common (either C4A or C4B) and appears to have a modest effect on host defense SLE, infections with encapsulated organisms, atherosclerosis Infections, glomerulonephritis, atypical hemolytic-uremic syndrome with GOF mutations. Atypical hemolytic-uremic syndrome Disseminated neisserial infections SLE, infections with encapsulated organisms, Ehlers-Danlos phenotype Hyperpigmentation, skin fragility SLE, infections with encapsulated organisms, Ehlers-Danlos phenotype SLE, infections with encapsulated organisms Associated features J Clin Immunol (2020) 40:24–64 55 AD AD AR AR CFHR1 CFHR2 CFHR3 CFHR4 CFHR5 THBD CD46 CD59 CD55 Factor H-related protein deficiencies AR or AD AR or AD MAC membrane attack complex, SLE systemic lupus erythematosus New disorders: 2; C1S AD GOF [105], C1R AD GOF [105] Total number of mutant genes in Table 8: 36 Total number of disorders in Table 8: 30 Thrombomodulin deficiency Membrane Cofactor Protein (CD46) deficiency Membrane Attack Complex Inhibitor (CD59) deficiency CD55 deficiency (CHAPLE disease) CFH Factor H deficiency AR XL AR CFD CFP CFI Factor D deficiency Properdin deficiency Factor I deficiency Inheritance Genetic defect Disease Table 8 (continued) 125240 107271 134371, 600889, 605336, 605337, 608593 188040 120920 134370 134350 300383 217030 Gene OMIM Normal CH50, AH50 Inhibitor of complement alternate pathway, decreased C3b binding Erythrocytes highly susceptible to complement-mediated lysis Hyperactivation of complement on endothelium Absent AH50 hemolytic activity Absent AH50 hemolytic activity Spontaneous activation of the alternative complement pathway with consumption of C3 Spontaneous activation of the alternative complement pathway with consumption of C3 Normal CH50, AH50, autoantibodies to Factor H., linked deletions of one or more CFHR genes leads to susceptibility autoantibody-mediated aHUS Laboratory features Protein losing enteropathy, thrombosis Atypical hemolytic-uremic syndrome Atypical hemolytic-uremic syndrome, infections, preeclampsia Hemolytic anemia, polyneuropathy Older onset atypical hemolytic-uremic syndrome, disseminated neisserial infections Neisserial infections Neisserial infections Infections, disseminated neisserial infections, atypical Hemolytic-uremic syndrome, preeclampsia Associated features 56 J Clin Immunol (2020) 40:24–64 Genetic defect FANCA FANCB FANCC BRCA2 FANCD2 FANCE FANCF XRCC9 FANCI BRIP1 FANCL FANCM PALB2 RAD51C SLX4 ERCC4 RAD51 BRCA1 UBE2T XRCC2 MAD2L2 RFWD3 SAMD9 SAMD9L DKC1 TERC TERT TINF2 RTEL1 TINF2 ACD NOLA3 NOLA2 WRAP53 TERT RTEL1 Fanconi anemia type A Fanconi anemia type B Fanconi anemia type C Fanconi anemia type D1 Fanconi anemia type D2 Fanconi anemia type E Fanconi anemia type F Fanconi anemia type G Fanconi anemia type I Fanconi anemia type J Fanconi anemia type L Fanconi anemia type M Fanconi anemia type N Fanconi anemia type O Fanconi anemia type P Fanconi anemia type Q Fanconi anemia type R Fanconi anemia type S Fanconi anemia type T Fanconi anemia type U Fanconi anemia type V Fanconi anemia type W MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, enteropathy) Ataxia pancytopenia syndrome DKCX1 DKCA1 DKCA2 DKCA3 DKCA4 DKCA5 DKCA6 DKCB1 DKCB2 DKCB3 DKCB4 DKCB5 Bone marrow failure Disease Table 9 XL AD AD AD AD AD AD AR AR AR AR AR AD GOF AR XLR AR AR AR AR AR AR AR AR AR AR AR AR AR AR AR AR AR AR AR AR AD GOF 305000 127550 187270 604319 616373 268130 616553 224230 613987 613988 613989 615190 611170 227650 300514 227645 605724 227646 600901 603467 614082 609053 609054 614083 618096 610832 613390 613951 615272 617244 617883 616435 617247 617243 617784 617053 Inheritance Gene OMIM Normal to low Low Normal to low Low Not reported Not reported Normal Normal to low B cells Normal to low T cells Normal to low NK, CNS, skeletal, skin, cardiac, GI, urogenital anomalies, increased chromosomal breakage Associated features Nail dystrophy, leukoplakia, bone marrow failure, severe B cell immunodeficiency, intrauterine growth retardation, growth HSC, myeloid Intrauterine growth retardation, cells gonadal abnormalities, adrenal failure, MDS with chromosome 7 aberrations, predisposition to infections, enteropathy, absent spleen HSC, myeloid MDS, neurological features cells HSC Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation; microcephaly, neurodevelopmental delay HSC Other affected cells Bone marrow failure with immune deficiency Major Category Dyskeratosis Congenita Fanconi Anemia Subcategory J Clin Immunol (2020) 40:24–64 57 PARN ACD SRP72 TP53 STN1 CTC1 DKCB6 DKCB7 BMFS1 (SRP72-deficiency) BMFS5 Coats plus syndrome AR AR AD AD AR AR 613129 617053 618165 602122 616553 616353 Inheritance Gene OMIM Normal Not reported NA NA T cells Normal Not reported Low B NA Normal to low Normal to low B cells Other affected cells retardation, microcephaly, cerebellar hypoplasia, and esophageal dysfunction Developmental delay, microcephaly, and cerebellar hypoplasia Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation; microcephaly, neurodevelopmental delay Bone marrow failure and congenital nerve deafness Erythroid hypoplasia, B cell deficiency Intrauterine growth retardation, premature aging, pancytopenia, hypocellular bone marrow, gastrointestinal hemorrhage due to vascular ectasia, intracranial calcification, abnormal telomeres Associated features Major Category Subcategory HSC hematopoietic stem cell, NK natural killer, CNS central nervous system, GI gastrointestinal, MDS myelodysplastic syndrome, DKCX X-inked dyskeratosis congenital, DKCA autosomal dominant dyskeratosis congenita, DKCB autosomal recessive dyskeratosis congenita, BMFS bone marrow failure syndrome Total number of mutant genes in Table 9: 43 Total number of disorders in Table 9: 43 Genetic defect Disease Table 9 (continued) 58 J Clin Immunol (2020) 40:24–64 AutoAb to CI inhibitor AutoAb to Complement Factor H AutoAb to various cytokines Acquired angioedema Atypical hemolytic uremic syndrome Increased CD8+ T cells Normal Normal No B cells Normal Normal Normal Normal Normal Normal Normal Normal Lymphocytosis B cell lymphocytosis Normal, but increased number of CD5+ B cells Circulating B cells Decreased Normal Normal Normal Normal Normal Normal Normal Normal Normal or increased Normal or increased Normal or increased Serum Ig Endocrinopathy, chronic mucocutaneous candidiasis/CMC Mycobacterial, fungal, Salmonella VZV infections/MSMD, or CID Staphylococcal infections/STAT3 deficiency Pulmonary alveolar proteinosis, cryptococcal meningitis, disseminated nocardiosis/CSF2RA deficiency Angioedema/C1 INH deficiency (hereditary angioedema) aHUS = Spontaneous activation of the alternative complement pathway Invasive bacterial, viral or opportunistic infections, autoimmunity, PRCA, lichen planus, cytopenia, colitis, chronic diarrhea Urticaria-like rash, arthropathy, neurological signs Eosinophilia, atopic dermatitis, urticarial rash, diarrhea Splenomegaly, lymphadenopathy, autoimmune cytopenias, Defective lymphocyte apoptosis/ALPS–FAS (=ALPS type Im) Splenomegaly, lymphadenopathy, autoimmune cytopenias, granulocytosis, monocytosis/ALPS-like Splenomegaly, lymphadenopathy, autoantibodies/ALPS-like Associated features/similar PID Total number of conditions for Table 10: 12 aHUS atypical hemolytic uremic syndrome, XL X-linked inheritance, AR autosomal recessive inheritance, AD autosomal dominant inheritance, LOF loss-of-function, GOF gain-of-function, PRCA pure red cell aplasia Thymoma with hypogammaglobulinemia (Good syndrome) AutoAb to GM-CSF Pulmonary alveolar proteinosis Normal Normal AutoAb to IL-6 Normal AutoAb to IL-17 and/or IL-22 Decreased naive T cells Normal Somatic mutation in STAT5B (GOF) AutoAb to IFNγ Normal Somatic mutation in NLRP3 Adult-onset immunodeficiency with susceptibility to mycobacteria Recurrent skin infection Increased CD4−CD8− double negative (DN) T alpha/beta cells Somatic mutation in NRAS (GOF) RAS-associated autoimmune leukoproliferative disease (RALD) Cryopyrinopathy, (Muckle-Wells/ CINCA/NOMID-like syndrome) Hypereosinophilic syndrome due to somatic mutations in STAT5b Associated with autoantibodies Chronic mucocutaneous candidiasis Normal Increased CD4−CD8−double negative (DN) αβ T cells Somatic mutation in KRAS (GOF) Somatic mutation in TNFRSF6 Associated with somatic mutations Autoimmune lymphoproliferative syndrome (ALPS–SFAS) Circulating T cells RAS-associated autoimmune leukoproliferative disease (RALD) Genetic defect/presumed pathogenesis Phenocopies of inborn errors of immunity Disease Table 10 J Clin Immunol (2020) 40:24–64 59 60 J Clin Immunol (2020) 40:24–64 Acknowledgments The members of the Inborn Errors of Immunity committee would like to thanks the International Union of Immunological Societies (IUIS) for funding, as well as CSL Behring, Baxalta and Shire/Takeda for providing educational grants to enable us to compile this classification update. 9. Compliance with Ethical Standards 10. Conflict of Interest The authors declare that they have no conflict of interest. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. References 1. 2. 3. 4. 5. 6. 7. 8. Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128. https://doi.org/10.1007/s10875-017-0464-9. Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, AlHerz W, et al. The 2017 IUIS phenotypic classification for primary Immunodeficiencies. J Clin Immunol. 2018;38(1):129–43. https:// doi.org/10.1007/s10875-017-0465-8. Casanova JL, Abel L. Human genetics of infectious diseases: unique insights into immunological redundancy. Semin Immunol. 2018;36:1–12. https://doi.org/10.1016/j.smim.2017. 12.008. Fischer A, Rausell A. What do primary immunodeficiencies tell us about the essentiality/redundancy of immune responses? Semin Immunol. 2018;36:13–6. https://doi.org/10.1016/j.smim.2017. 12.001. Zhang SY, Jouanguy E, Zhang Q, Abel L, Puel A, Casanova JL. Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism. Curr Opin Immunol. 2019;59:88–100. https://doi.org/10.1016/j. coi.2019.03.008. Bucciol G, Moens L, Bosch B, Bossuyt X, Casanova JL, Puel A, et al. Lessons learned from the study of human inborn errors of innate immunity. J Allergy Clin Immunol. 2019;143(2):507–27. https://doi.org/10.1016/j.jaci.2018.07.013. Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, et al. Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 2016;138(4):957–69. https://doi.org/10. 1016/j.jaci.2016.08.003. Picard C, Fischer A. Contribution of high-throughput DNA sequencing to the study of primary immunodeficiencies. Eur J 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. Immunol. 2014;44(10):2854–61. https://doi.org/10.1002/eji. 201444669. Zhang Q, Frange P, Blanche S, Casanova JL. Pathogenesis of infections in HIV-infected individuals: insights from primary immunodeficiencies. Curr Opin Immunol. 2017;48:122–33. https:// doi.org/10.1016/j.coi.2017.09.002. Kerner G, Ramirez-Alejo N, Seeleuthner Y, Yang R, Ogishi M, Cobat A, et al. Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry. Proc Natl Acad Sci U S A. 2019;116(21):10430–4. https://doi.org/ 10.1073/pnas.1903561116. Leiding JW, Forbes LR. Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary Immunodysregulatory diseases. J Allergy Clin Immunol Pract. 2019;7(3):761–73. https://doi.org/10.1016/j.jaip.2018.12.017. Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199–227. https://doi.org/10.1146/annurev.immunol.021908.132649. Fischer A, Rausell A. Primary immunodeficiencies suggest redundancy within the human immune system. Sci Immunol. 2016;1(6). https://doi.org/10.1126/sciimmunol.aah5861. Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, et al. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann N Y Acad Sci. 2015;1358:82–94. https://doi.org/10.1111/nyas.12878. Ma CS, Tangye SG. Flow Cytometric-based analysis of defects in lymphocyte differentiation and function due to inborn errors of immunity. Front Immunol. 2019;10:2108. https://doi.org/10. 3389/fimmu.2019.02108. Bruton OC. Agammaglobulinemia Pediatrics. 1952;9(6):722–8. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137–49. https://doi.org/10.1084/jem.20140520. Byun M, Abhyankar A, Lelarge V, Plancoulaine S, Palanduz A, Telhan L, et al. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J Exp Med. 2010;207(11):2307–12. https://doi.org/10.1084/jem. 20101597. Beziat V, Li J, Lin JX, Ma CS, Li P, Bousfiha A, et al. A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity. Sci Immunol. 2018;3(24). https://doi.org/10.1126/sciimmunol.aat4956. Frey-Jakobs S, Hartberger JM, Fliegauf M, Bossen C, Wehmeyer ML, Neubauer JC, et al. ZNF341 controls STAT3 expression and thereby immunocompetence. Sci Immunol. 2018;3(24). https:// doi.org/10.1126/sciimmunol.aat4941. Shahin T, Aschenbrenner D, Cagdas D, Bal SK, Conde CD, Garncarz W, et al. Selective loss of function variants in IL6ST cause hyper-IgE syndrome with distinct impairments of T-cell phenotype and function. Haematologica. 2019;104(3):609–21. https://doi.org/10.3324/haematol.2018.194233. Schwerd T, Twigg SRF, Aschenbrenner D, Manrique S, Miller KA, Taylor IB, et al. A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis. J Exp Med. 2017;214(9):2547–62. https://doi.org/10.1084/ jem.20161810. Spencer S, Kostel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, et al. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J Exp Med. 2019;216(9):1986–98. https://doi.org/10.1084/jem.20190344. J Clin Immunol (2020) 40:24–64 24. Nahum A, Sharfe N, Broides A, Dadi H, Naghdi Z, Mandola AB, et al. Defining the biological responses of IL-6 by the study of a novel IL-6 receptor chain (IL6R) immunodeficiency. J Allergy Clin Immunol. 2019. https://doi.org/10.1016/j.jaci.2019.11.015. 25. Ma CA, Stinson JR, Zhang Y, Abbott JK, Weinreich MA, Hauk PJ, et al. Germline hypomorphic CARD11 mutations in severe atopic disease. Nat Genet. 2017;49(8):1192–201. https://doi.org/ 10.1038/ng.3898. 26. Dorjbal B, Stinson JR, Ma CA, Weinreich MA, Miraghazadeh B, Hartberger JM, et al. Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. J Allergy Clin Immunol. 2019;143(4):1482–95. https://doi.org/10. 1016/j.jaci.2018.08.013. 27. Klammt J, Neumann D, Gevers EF, Andrew SF, Schwartz ID, Rockstroh D, et al. Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation. Nat Commun. 2018;9(1):2105. https://doi.org/10. 1038/s41467-018-04521-0. 28. Lu HY, Bauman BM, Arjunaraja S, Dorjbal B, Milner JD, Snow AL, et al. The CBM-opathies-A rapidly expanding Spectrum of human inborn errors of immunity caused by mutations in the CARD11-BCL10-MALT1 complex. Front Immunol. 2018;9: 2078. https://doi.org/10.3389/fimmu.2018.02078. 29. Nadeau K, Hwa V, Rosenfeld RG. STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J Pediatr. 2011;158(5):701–8. https://doi.org/ 10.1016/j.jpeds.2010.12.042. 30. Boisson B, Wang YD, Bosompem A, Ma CS, Lim A, Kochetkov T, et al. A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(−) B cells. J Clin Invest. 2013;123(11): 4781–5. https://doi.org/10.1172/JCI71927. 31. Ben-Ali M, Yang J, Chan KW, Ben-Mustapha I, Mekki N, Benabdesselem C, et al. Homozygous transcription factor 3 gene (TCF3) mutation is associated with severe hypogammaglobulinemia and B-cell acute lymphoblastic leukemia. J Allergy Clin Immunol. 2017;140(4):1191–4 e4. https://doi.org/10.1016/j.jaci.2017.04.037. 32. Qureshi S, Sheikh MDA, Qamar FN. Autosomal recessive Agammaglobulinemia - first case with a novel TCF3 mutation from Pakistan. Clin Immunol. 2019;198:100–1. https://doi.org/ 10.1016/j.clim.2018.07.016. 33. Cardinez C, Miraghazadeh B, Tanita K, da Silva E, Hoshino A, Okada S, et al. Gain-of-function IKBKB mutation causes human combined immune deficiency. J Exp Med. 2018;215(11):2715– 24. https://doi.org/10.1084/jem.20180639. 34. Pannicke U, Baumann B, Fuchs S, Henneke P, Rensing-Ehl A, Rizzi M, et al. Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med. 2013;369(26):2504–14. https://doi.org/10.1056/NEJMoa1309199. 35. Sogkas G, Fedchenko M, Dhingra A, Jablonka A, Schmidt RE, Atschekzei F. Primary immunodeficiency disorder caused by phosphoinositide 3-kinase delta deficiency. J Allergy Clin Immunol. 2018;142(5):1650–3 e2. https://doi.org/10.1016/j.jaci. 2018.06.039. 36. Cohen SB, Bainter W, Johnson JL, Lin TY, Wong JCY, Wallace JG, et al. Human primary immunodeficiency caused by expression of a kinase-dead p110delta mutant. J Allergy Clin Immunol. 2019;143(2):797–9 e2. https://doi.org/10.1016/j.jaci.2018.10.005. 37. Tangye SG, Bier J, Lau A, Nguyen T, Uzel G, Deenick EK. Immune Dysregulation and disease pathogenesis due to activating mutations in PIK3CD-the Goldilocks' effect. J Clin Immunol. 2019;39(2):148–58. https://doi.org/10.1007/s10875-019-006129. 38. Boutboul D, Kuehn HS, Van de Wyngaert Z, Niemela JE, Callebaut I, Stoddard J, et al. Dominant-negative IKZF1 61 mutations cause a T, B, and myeloid cell combined immunodeficiency. J Clin Invest. 2018;128(7):3071–87. https://doi.org/10. 1172/JCI98164. 39. Kuehn HS, Boisson B, Cunningham-Rundles C, Reichenbach J, Stray-Pedersen A, Gelfand EW, et al. Loss of B cells in patients with heterozygous mutations in IKAROS. N Engl J Med. 2 0 1 6 ; 3 7 4 ( 11 ) : 1 0 3 2 – 4 3 . h t t p s : / / d o i . o rg / 1 0 . 1 0 5 6 / NEJMoa1512234. 40. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154–64. https://doi.org/10.1182/blood2015-11-679902. 41. Alkhairy OK, Rezaei N, Graham RR, Abolhassani H, Borte S, Hultenby K, et al. RAC2 loss-of-function mutation in 2 siblings with characteristics of common variable immunodeficiency. J Allergy Clin Immunol. 2015;135(5):1380-4 e1-5. https://doi.org/ 10.1016/j.jaci.2014.10.039. 42. Hsu AP, Donko A, Arrington ME, Swamydas M, Fink D, Das A, et al. Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects. Blood. 2019;133(18):1977–88. https://doi.org/10.1182/blood-2018-11886028. 43. Lougaris V, Chou J, Beano A, Wallace JG, Baronio M, Gazzurelli L, et al. A monoallelic activating mutation in RAC2 resulting in a combined immunodeficiency. J Allergy Clin Immunol. 2019;143(4):1649–53 e3. https://doi.org/10.1016/j.jaci.2019.01. 001. 44. Sharapova SO, Haapaniemi E, Sakovich IS, Kostyuchenko LV, Donko A, Dulau-Florea A, et al. Heterozygous activating mutation in RAC2 causes infantile-onset combined immunodeficiency with susceptibility to viral infections. Clin Immunol. 2019;205:1– 5. https://doi.org/10.1016/j.clim.2019.05.003. 45. Smits BM, Lelieveld PHC, Ververs FA, Turkenburg M, de Koning C, van Dijk M, et al. A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease. Clin Immunol. 2019;108248. https://doi.org/10.1016/j.clim.2019. 108248. 46. Hernandez N, Melki I, Jing H, Habib T, Huang SSY, Danielson J, et al. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. J Exp Med. 2018;215(10):2567–85. https://doi.org/10.1084/jem.20180628. 47. Belkaya S, Michailidis E, Korol CB, Kabbani M, Cobat A, Bastard P, et al. Inherited IL-18BP deficiency in human fulminant viral hepatitis. J Exp Med. 2019;216(8):1777–90. https://doi.org/ 10.1084/jem.20190669. 48. Serwas NK, Hoeger B, Ardy RC, Stulz SV, Sui Z, Memaran N, et al. Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. Nat Commun. 2019;10(1):3106. https://doi.org/10.1038/ s41467-019-10812-x. 49. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–40. https://doi. org/10.1126/science.aaa1663. 50. Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic Tlymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932–46. https://doi.org/10.1016/j.jaci. 2018.02.055. 51. Martinez-Barricarte R, Markle JG, Ma CS, Deenick EK, RamirezAlejo N, Mele F, et al. Human IFN-gamma immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol. 2018;3(30). https://doi.org/10.1126/sciimmunol. aau6759. 62 52. Kong XF, Martinez-Barricarte R, Kennedy J, Mele F, Lazarov T, Deenick EK, et al. Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. Nat Immunol. 2018;19(9):973–85. https://doi.org/10.1038/ s41590-018-0178-z. 53. Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, et al. Loss of human ICOSL results in combined immunodeficiency. J Exp Med. 2018;215(12):3151–64. https://doi.org/10. 1084/jem.20180668. 54. Conde CD, Petronczki OY, Baris S, Willmann KL, Girardi E, Salzer E, et al. Polymerase delta deficiency causes syndromic immunodeficiency with replicative stress. J Clin Invest. 2019;129(10):4194–206. https://doi.org/10.1172/JCI128903. 55. Cui Y, Keles S, Charbonnier LM, Jule AM, Henderson L, Celik SC, et al. Combined immunodeficiency due to a loss of function mutation in DNA Polymerase Delta 1. J Allergy Clin Immunol. 2019. https://doi.org/10.1016/j.jaci.2019.10.004. 56. Badran YR, Dedeoglu F, Leyva Castillo JM, Bainter W, Ohsumi TK, Bousvaros A, et al. Human RELA haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration. J Exp Med. 2017;214(7):1937–47. https://doi.org/10.1084/jem. 20160724. 57. Comrie WA, Faruqi AJ, Price S, Zhang Y, Rao VK, Su HC, et al. RELA haploinsufficiency in CD4 lymphoproliferative disease with autoimmune cytopenias. J Allergy Clin Immunol. 2018;141(4):1507–10 e8. https://doi.org/10.1016/j.jaci.2017.11. 036. 58. Beaussant-Cohen S, Jaber F, Massaad MJ, Weeks S, Jones J, Alosaimi MF, et al. Combined immunodeficiency in a patient with c-Rel deficiency. J Allergy Clin Immunol. 2019;144(2):606–8 e4. https://doi.org/10.1016/j.jaci.2019.05.003. 59. Calzoni E, Platt CD, Keles S, Kuehn HS, Beaussant-Cohen S, Zhang Y, et al. F-BAR domain only protein 1 (FCHO1) deficiency is a novel cause of combined immune deficiency in human subjects. J Allergy Clin Immunol. 2019;143(6):2317–21 e12. https:// doi.org/10.1016/j.jaci.2019.02.014. 60. Maffucci P, Chavez J, Jurkiw TJ, O'Brien PJ, Abbott JK, Reynolds PR, et al. Biallelic mutations in DNA ligase 1 underlie a spectrum of immune deficiencies. J Clin Invest. 2018;128(12):5489–504. https://doi.org/10.1172/JCI99629. 61. Bosticardo M, Yamazaki Y, Cowan J, Giardino G, Corsino C, Scalia G, et al. Heterozygous FOXN1 variants cause low TRECs and severe T cell Lymphopenia, revealing a crucial role of FOXN1 in supporting early Thymopoiesis. Am J Hum Genet. 2019;105(3):549–61. https://doi.org/10.1016/j.ajhg.2019.07.014. 62. Lyons JJ, Liu Y, Ma CA, Yu X, O'Connell MP, Lawrence MG, et al. ERBIN deficiency links STAT3 and TGF-beta pathway defects with atopy in humans. J Exp Med. 2017;214(3):669–80. https:// doi.org/10.1084/jem.20161435. 63. Schepers D, Tortora G, Morisaki H, MacCarrick G, Lindsay M, Liang D, et al. A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3. Hum Mutat. 2018;39(5):621–34. https://doi.org/10.1002/humu.23407. 64. Fabre A, Charroux B, Martinez-Vinson C, Roquelaure B, Odul E, Sayar E, et al. SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. Am J Hum Genet. 2012;90(4): 689–92. https://doi.org/10.1016/j.ajhg.2012.02.009. 65. Huppke P, Weissbach S, Church JA, Schnur R, Krusen M, DrehaKulaczewski S, et al. Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder. Nat Commun. 2017;8(1):818. https://doi.org/10.1038/s41467-017-00932-7. 66. Rodriguez R, Fournier B, Cordeiro DJ, Winter S, Izawa K, Martin E, et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J Exp Med. 2019. https://doi.org/10.1084/jem.20190678. J Clin Immunol (2020) 40:24–64 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. Anzilotti C, Swan DJ, Boisson B, Deobagkar-Lele M, Oliveira C, Chabosseau P, et al. An essential role for the Zn(2+) transporter ZIP7 in B cell development. Nat Immunol. 2019;20(3):350–61. https://doi.org/10.1038/s41590-018-0295-8. Broderick L, Yost S, Li D, McGeough MD, Booshehri LM, Guaderrama M, et al. Mutations in topoisomerase IIbeta result in a B cell immunodeficiency. Nat Commun. 2019;10(1):3644. https://doi.org/10.1038/s41467-019-11570-6. Bouafia A, Lofek S, Bruneau J, Chentout L, Lamrini H, Trinquand A, et al. Loss of ARHGEF1 causes a human primary antibody deficiency. J Clin Invest. 2019;129(3):1047–60. https://doi.org/ 10.1172/JCI120572. Keller B, Shoukier M, Schulz K, Bhatt A, Heine I, Strohmeier V, et al. Germline deletion of CIN85 in humans with X chromosomelinked antibody deficiency. J Exp Med. 2018;215(5):1327–36. https://doi.org/10.1084/jem.20170534. Schubert D, Klein MC, Hassdenteufel S, Caballero-Oteyza A, Yang L, Proietti M, et al. Plasma cell deficiency in human subjects with heterozygous mutations in Sec61 translocon alpha 1 subunit (SEC61A1). J Allergy Clin Immunol. 2018;141(4):1427–38. https://doi.org/10.1016/j.jaci.2017.06.042. Mauhin W, Habarou F, Gobin S, Servais A, Brassier A, Grisel C, et al. Update on Lysinuric protein intolerance, a multi-faceted disease retrospective cohort analysis from birth to adulthood. Orphanet J Rare Dis. 2017;12(1):3. https://doi.org/10.1186/ s13023-016-0550-8. Fernandez IZ, Baxter RM, Garcia-Perez JE, Vendrame E, Ranganath T, Kong DS, et al. A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation. J Exp Med. 2019;216(6):1255–67. https://doi.org/10.1084/jem. 20182015. Zhang Z, Gothe F, Pennamen P, James JR, McDonald D, Mata CP, et al. Human interleukin-2 receptor beta mutations associated with defects in immunity and peripheral tolerance. J Exp Med. 2019;216(6):1311–27. https://doi.org/10.1084/jem.20182304. Has C, Castiglia D, del Rio M, Diez MG, Piccinni E, Kiritsi D, et al. Kindler syndrome: extension of FERMT1 mutational spectrum and natural history. Hum Mutat. 2011;32(11):1204–12. https://doi. org/10.1002/humu.21576. Kotlarz D, Marquardt B, Baroy T, Lee WS, Konnikova L, Hollizeck S, et al. Human TGF-beta1 deficiency causes severe inflammatory bowel disease and encephalopathy. Nat Genet. 2018;50(3):344–8. https://doi.org/10.1038/s41588-018-0063-6. Cuchet-Lourenco D, Eletto D, Wu C, Plagnol V, Papapietro O, Curtis J, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science. 2018;361(6404):810–3. https://doi.org/10.1126/science.aar2641. Li Y, Fuhrer M, Bahrami E, Socha P, Klaudel-Dreszler M, Bouzidi A, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2019;116(3):970–5. https://doi.org/10.1073/pnas.1813582116. Alosaimi MF, Hoenig M, Jaber F, Platt CD, Jones J, Wallace J, et al. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. J Allergy Clin Immunol. 2019;144(2):574–83 e5. https://doi.org/10.1016/j.jaci.2019.03. 002. Somekh I, Thian M, Medgyesi D, Gulez N, Magg T, Gallon Duque A, et al. CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood. 2019. https://doi. org/10.1182/blood.2019000644. Carapito R, Konantz M, Paillard C, Miao Z, Pichot A, Leduc MS, et al. Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-diamond-like features. J Clin Invest. 2017;127(11):4090–103. https://doi.org/10.1172/ JCI92876. 63 J Clin Immunol (2020) 40:24–64 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. Bellanne-Chantelot C, Schmaltz-Panneau B, Marty C, Fenneteau O, Callebaut I, Clauin S, et al. Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-diamondlike syndrome. Blood. 2018;132(12):1318–31. https://doi.org/10. 1182/blood-2017-12-820308. Dhanraj S, Matveev A, Li H, Lauhasurayotin S, Jardine L, Cada M, et al. Biallelic mutations in DNAJC21 cause Shwachman-diamond syndrome. Blood. 2017;129(11):1557–62. https://doi.org/ 10.1182/blood-2016-08-735431. Arnadottir GA, Norddahl GL, Gudmundsdottir S, Agustsdottir AB, Sigurdsson S, Jensson BO, et al. A homozygous loss-offunction mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat Commun. 2018;9(1):4447. https:// doi.org/10.1038/s41467-018-06964-x. Thomas DC, Charbonnier LM, Schejtman A, Aldhekri H, Coomber EL, Dufficy ER, et al. EROS/CYBC1 mutations: decreased NADPH oxidase function and chronic granulomatous disease. J Allergy Clin Immunol. 2019;143(2):782–5 e1. https:// doi.org/10.1016/j.jaci.2018.09.019. de Jong SJ, Crequer A, Matos I, Hum D, Gunasekharan V, Lorenzo L, et al. The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to beta-papillomaviruses. J Exp Med. 2018;215(9):2289–310. https://doi.org/10.1084/jem. 20170308. Hernandez N, Bucciol G, Moens L, Le Pen J, Shahrooei M, Goudouris E, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. 2019;216(9):2057–70. https://doi.org/ 10.1084/jem.20182295. Ogunjimi B, Zhang SY, Sorensen KB, Skipper KA, CarterTimofte M, Kerner G, et al. Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections. J Clin Invest. 2017;127(9):3543–56. https://doi.org/10.1172/JCI92280. Carter-Timofte ME, Hansen AF, Mardahl M, Fribourg S, Rapaport F, Zhang SY, et al. Varicella-zoster virus CNS vasculitis and RNA polymerase III gene mutation in identical twins. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e500. https://doi.org/ 10.1212/NXI.0000000000000500. Zhang SY, Clark NE, Freije CA, Pauwels E, Taggart AJ, Okada S, et al. Inborn errors of RNA lariat metabolism in humans with brainstem viral infection. Cell. 2018;172(5):952–65 e18. https:// doi.org/10.1016/j.cell.2018.02.019. Guerin A, Kerner G, Marr N, Markle JG, Fenollar F, Wong N, et al. IRF4 haploinsufficiency in a family with Whipple's disease. Elife. 2018;7. https://doi.org/10.7554/eLife.32340. Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest. 2015;125(11):4196–211. https://doi.org/10.1172/ JCI81260. Rodero MP, Tesser A, Bartok E, Rice GI, Della Mina E, Depp M, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;8(1):2176. https://doi.org/10. 1038/s41467-017-01932-3. Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshedi F, Alhashmi N, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43(12):1186–8. https://doi.org/10.1038/ng.975. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. Ozcakar ZB, Foster J 2nd, Diaz-Horta O, Kasapcopur O, Fan YS, Yalcinkaya F, et al. DNASE1L3 mutations in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 2013;65(8):2183– 9. https://doi.org/10.1002/art.38010. Carbonella A, Mancano G, Gremese E, Alkuraya FS, Patel N, Gurrieri F, et al. An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. Lupus. 2017;26(7):768–72. https://doi.org/10.1177/0961203316676382. Cho K, Yamada M, Agematsu K, Kanegane H, Miyake N, Ueki M, et al. Heterozygous mutations in OAS1 cause infantile-onset pulmonary alveolar Proteinosis with Hypogammaglobulinemia. Am J Hum Genet. 2018;102(3):480–6. https://doi.org/10.1016/j. ajhg.2018.01.019. Zhong FL, Mamai O, Sborgi L, Boussofara L, Hopkins R, Robinson K, et al. Germline NLRP1 mutations cause skin inflammatory and Cancer susceptibility syndromes via Inflammasome activation. Cell. 2016;167(1):187–202 e17. https://doi.org/10. 1016/j.cell.2016.09.001. Drutman SB, Haerynck F, Zhong FL, Hum D, Hernandez NJ, Belkaya S, et al. Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis. Proc Natl Acad Sci U S A. 2019;116(38):19055– 63. https://doi.org/10.1073/pnas.1906184116. Parlato M, Charbit-Henrion F, Pan J, Romano C, Duclaux-Loras R, Le Du MH, et al. Human ALPI deficiency causes inflammatory bowel disease and highlights a key mechanism of gut homeostasis. EMBO Mol Med. 2018;10(4). https://doi.org/10.15252/emmm. 201708483. Li Q, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, et al. Variants in TRIM22 that affect NOD2 signaling are associated with very-early-onset inflammatory bowel disease. Gastroenterology. 2016;150(5):1196–207. https://doi.org/10. 1053/j.gastro.2016.01.031. de Jesus AA, Brehm A, VanTries R, Pillet P, Parentelli AS, Montealegre Sanchez GA, et al. Novel proteasome assembly c h a p e r o n e m u t a t i o n s i n P S M G 2 / PA C 2 c a u s e t h e autoinflammatory interferonopathy CANDLE/PRAAS4. J Allergy Clin Immunol. 2019;143(5):1939–43 e8. https://doi.org/ 10.1016/j.jaci.2018.12.1012. Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet. 2018;50(12):1650–7. https://doi.org/10.1038/s41588-018-02514. Polprasert C, Takeuchi Y, Kakiuchi N, Yoshida K, Assanasen T, Sitthi W, et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Adv. 2019;3(4):588–95. https://doi.org/10.1182/bloodadvances. 2018028340. Kapferer-Seebacher I, Pepin M, Werner R, Aitman TJ, Nordgren A, Stoiber H, et al. Periodontal Ehlers-Danlos syndrome is caused by mutations in C1R and C1S, which encode subcomponents C1r and C1s of complement. Am J Hum Genet. 2016;99(5):1005–14. https://doi.org/10.1016/j.ajhg.2016.08.019. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 64 J Clin Immunol (2020) 40:24–64 Affiliations Stuart G. Tangye 1,2 & Waleed Al-Herz 3 & Aziz Bousfiha 4 & Talal Chatila 5 & Charlotte Cunningham-Rundles 6 & Amos Etzioni 7 & Jose Luis Franco 8 & Steven M. Holland 9 & Christoph Klein 10 & Tomohiro Morio 11 & Hans D. Ochs 12 & Eric Oksenhendler 13 & Capucine Picard 14,15 & Jennifer Puck 16 & Troy R. Torgerson 12 & Jean-Laurent Casanova 17,18,19,20 & Kathleen E. Sullivan 21 1 Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW 2010, Australia 12 Department of Pediatrics, University of Washington and Seattle Children’s Research Institute, Seattle, WA, USA 2 Faculty of Medicine, St Vincent’s Clinical School, UNSW, Sydney, NSW, Australia 13 Department of Clinical Immunology, Hôpital Saint-Louis, APHP, University Paris Diderot, Sorbonne Paris Cité, Paris, France 3 Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait 14 Study Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, APHP, Paris, France 4 King Hassan II University, Laboratoire d’Immunologie Clinique, d’Inflammation et d’Allergy LICIA at Faculty of Medicine and Pharmacy, Clinical Immunology Unit, Pediatric Infectiouse Disease Department, Children’s Hospital, Ibn Rochd University Hospital, Casablanca, Morocco 15 Paris University, Laboratory of Lymphocyte Activation and Susceptibility to EBV, INSERM UMR1163, Imagine Institute, Necker Hospital for Sick Children, Paris, France 16 Department of Pediatrics, University of California San Francisco and UCSF Benioff Children’s Hospital, San Francisco, CA, USA 17 Departments of Medicine and Pediatrics, Mount Sinai School of Medicine, New York, NY, USA St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA 18 Howard Hughes Medical Institute, New York, NY, USA 7 Ruth’s Children’s Hospital-Technion, Haifa, Israel 19 8 Grupo de Inmunodeficiencias Primarias, Facultad de Medicina, Universidad de Antioquia UdeA, Medellin, Colombia Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR1163, Imagine Institute, Necker Hospital for Sick Children, Paris University, Paris, France 9 Laboratory of Clinical Immunology & Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA 20 Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France 10 Dr von Hauner Children’s Hospital, Ludwig-MaximiliansUniversity Munich, Munich, Germany 21 11 Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan Division of Allergy Immunology, Department of Pediatrics, The Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 5 6 Division of Immunology, Children’s Hospital Boston, Boston, MA, USA